=> s 11-12 L4 56 (L1 OR L2) => s 14 and 13

=> d l5 ibib abs 1-12

L5

L5 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1265933 HCAPLUS

TITLE: Light-stable vitamin E by inclusion in .gamma

.-cyclodextrin

AUTHOR(S): Regiert, Marlies

12 L4 AND L3

CORPORATE SOURCE: Wacker Chemie AG, Burghausen, 84489, Germany

SOURCE: NutraCos (2006), 5(4), VD2-VD6
CODEN: NUTRCP; ISSN: 1720-4011

PUBLISHER: B5 srl
DOCUMENT TYPE: Journal
LANGUAGE: English

Vitamin E is known as the "protective vitamin" which, in its alc., AB effective form, is so sensitive to light and air that it needs protecting itself. Microencapsulation, which is occasionally employed, does not completely succeed in satisfactorily stabilizing the α -tocopherol, and it involves certain disadvantages in terms of application technol. Until now, therefore, the cosmetics and pharmaceutical industries have not had any truly light-stable α -tocopherol at their disposal. shortcoming has been remedied by a new development by Wacker Fine Chems., in which α -tocopherol is effectively protected by its mol. inclusion in cyclodextrin, from where it is released in a controlled manner. The product was developed by complexing with .gamma .cyclodextrin, and is resistant to the effects of air and light, as has been demonstrated by studies of its thermal, storage and light stability. Under conditions like those found after a formulation has been applied to the skin, $d-\alpha$ -tocopherol is released from this host-guest inclusion compound in a controlled way. This means that $d-\alpha$ -tocopherol has become available in a light-stable form for use in cosmetic products.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:795378 HCAPLUS

DOCUMENT NUMBER: 145:212937

TITLE: Solvent-free dispersions of 1:1 or 2:1

cyclodextrin-perfume complexes

INVENTOR(S): Regiert, Marlies; Zeh, Harald; Kupka,

Michaela

PATENT ASSIGNEE(S): Wacker Polymer Systems G.m.b.H. & Co. K.-G., Germany

SOURCE: Ger. Offen., 19pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE			APPLICATION NO.						DATE			
DE 102005005633 A1 WO 2006084586 A1					20060810			DE 2005-102005005633 WO 2006-EP694					20050208					
₩:	CN,	CO,	CR,	AM, CU,	AT,	AU, DE, ID,	DK,	BA, DM,	BB, DZ,	BG, EC,	BR, EE,	BW, EG,	ES,	BZ, FI,	CA, GB,	CH, GD,		

```
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
                                             DE 2005-102005005633A 20050208
PRIORITY APPLN. INFO.:
     The title complexes, which are atable for several years, are prepared from
AB
     \alpha-, \beta-, or . gamma.-cyclodextrin,
     methyl-\beta- or -. gamma.-Cyclodextrin, or
     hydroxypropyl-\beta- or -. gamma.-Cyclodextrin. A
     mixture of \beta- cyclodextrin (H2O content 10%) and 1500 mL H2O
     was heated to 70°, mixed with 202 g citral, stirred at 70°
     for 1 day, and dried in vacuo to give 1700 g complex containing 10% citral and
     4.5% H2O. Use of the complexes in coatings is exemplified.
                               THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
                          4
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
L5
                         2006:448306 HCAPLUS
ACCESSION NUMBER:
                         145:235316
DOCUMENT NUMBER:
                         Stabilizing linoleic acid by complexation with
TITLE:
                         \alpha- cyclodextrin
                         Regiert, Marlies
AUTHOR (S):
                         Wacker-Chemie AG, Burghausen, Germany
CORPORATE SOURCE:
                         Cosmetics & Toiletries (2006), 121(4), 43-50
SOURCE:
                         CODEN: CTOIDG; ISSN: 0361-4387
                         Allured Publishing Corp.
PUBLISHER:
                         Journal; General Review
DOCUMENT TYPE:
                         English
LANGUAGE:
     A review. In the form of a mol. inclusion compound with \alpha-
AB
     cyclodextrin, linoleic acid effectively is protected against
     oxidation Investigations into the storage and light stability, olfactory
     tests and headspace anal. of the formulations give evidence of the
     stability of a suitable inclusion compound
                                THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
                          11
REFERENCE COUNT:
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
L5
                          2005:657391 HCAPLUS
ACCESSION NUMBER:
                          143:158697
DOCUMENT NUMBER:
                         Light stability of vitamin E by encapsulation in .
TITLE:
                          gamma.-cyclodextrin
                          Regiert, M.
AUTHOR (S):
                          Germany -
CORPORATE SOURCE:
                          SOFW Journal (2005), 131(5), 10, 12-18
SOURCE:
                          CODEN: SOFJEE; ISSN: 0942-7694
                          Verlag fuer Chemische Industrie H. Ziolkowsky
PUBLISHER:
                          Journal; General Review
DOCUMENT TYPE:
                          German
LANGUAGE:
     A review on skin aging by UV radiation radical scavenging by vitamin E in
AB
     skin protection and skin care products, effectiveness of
     \alpha-tocopherol and its ester, mol. encapsulation of \alpha-tocopherol
     in .gamma.-cyclodextrin, and stability of the .
     gamma.-cyclodextrin/\alpha-tocopherol complexes in
     cosmetic formulations.
                                THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
L5
```

Page 2

ACCESSION NUMBER: 2004:402912 HCAPLUS

DOCUMENT NUMBER: 140:412001

Cosmetic composition comprising a complex of TITLE:

cyclodextrin and vitamin F

Regiert, Marlies; Kupka, Michaela INVENTOR(S):

Wacker-Chemie GmbH, Germany PATENT ASSIGNEE(S):

Eur. Pat. Appl., 17 pp. SOURCE:

CODEN: EPXXDW

Patent DOCUMENT TYPE: LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
·	A1 20040519	EP 2003-26137	20031113
	B1 20051019 DE, DK, ES, FR,	GB, GR, IT, LI, LU, NL	, SE, MC, PT,
IE, SI, LT,	LV, FI, RO, MK,	CY, AL, TR, BG, CZ, EE	, HU, SK
DE 10253042	A1 20040603	DE 2002-10253042	20021114
KR 2004042827	A 20040520	KR 2003-77579	20031104
		US 2003-712703	
JP 2004161775	A 20040610	JP 2003-385675	20031114
PRIORITY APPLN. INFO.:		DE 2002-10253042	A 20021114
		dermatol. compns. that	contain
complexes of vitami	.n F with α , β , or	. gamma	•
cyclodextrin. Addr	l. substances in	the formulations are:	silicone
·		nces, gelation agents,	·
		s, pigments, tanning a	gents, etc.
-		ed with 100 g water;	
		genized and stirred fo	
	-	persed in water, filte	
		mposition contained (w	eight/weight%):α-
cyclodextrin-linoli	-		
-		5; octyl palmitate 2.5	
-		esquiisostearate 2.0;	-
	_ ,	2.0; octyl dimethicon	e ethoxy
glycoside, cyclomet			
		xide 2.0; glycerin 2.0	; methylparaben
0.1; sodium chlorid			
REFERENCE COUNT:	12 THERE ARE	12 CITED REFERENCES AV	AILABLE FOR THIS

ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN L5

2003:744004 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

140:344479

TITLE:

Cyclodextrins: an other tool for

encapsulation

AUTHOR (S):

Regiert, M.

CORPORATE SOURCE:

Cyclodextrin for Personal Care, Flavour/Fragrance, Biotech Wacker Specialties Customized Chemical Solutions, Wacker-Chemie GmbH, Burghausen, 84489,

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Germany

SOURCE:

SOFW Journal (2003), 129(6), 2, 4, 6, 8

CODEN: SOFJEE; ISSN: 0942-7694

PUBLISHER:

Verlag fuer Chemische Industrie H. Ziolkowsky

DOCUMENT TYPE: Journal; General Review

LANGUAGE:

English

A review. Cyclodextrins are ring-shaped cylindrical mols. ABcomprising a number of linked glucose mols. Their complexes have the ability to wrap each individual mol. of the active ingredient, a process known as complexation. The cyclodextrins act as the host and the accommodated mol. is the guest, which can be any mols. that are both small

enough to fit inside the cavity and are non-polar enough to interact with the lipophilic internal surface. In cosmetic and personal care products, the resulting complex releases the cosmetic substances on the skin, exactly where it is needed and very reliably too. The advantages of using cyclodextrins in various products are described.

L5 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532338 HCAPLUS

DOCUMENT NUMBER: 139:90089

TITLE: A complex of β - or . gamma.-

cyclodextrin and α-tocopherol

INVENTOR(S): Regiert, Marlies; Kupka, Michaela

PATENT ASSIGNEE(S): Wacker-Chemie Gmbh, Germany SOURCE: U.S. Pat. Appl. Publ., 13 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
				-	
US 2003130231	A1	20030710	US 2002-323019		20021219
DE 10200657	A1	20030724	DE 2002-10200657		20020110
FR 2834512	A1	20030711	FR 2003-122		20030108
FR 2834512	B1	20060421			
JP 2003238402	A	20030827	JP 2003-2255		20030108
PRIORITY APPLN. INFO.:			DE 2002-10200657	A	20020110

AB A method of stabilization of α -tocopherol against oxidative decomposition or UV-induced decomposition is provided. The method comprises preparation of complexes of β - cyclodextrin or .gamma.-

cyclodextrin and α -tocopherol in a cyclodextrin

/tocopherol molar ratio of 2:1. The complexes are used in cosmetic formulations, such as a sunscreen cream, an after-sun lotion, a liquid makeup, or a body emulsion.

L5 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:144110 HCAPLUS

DOCUMENT NUMBER: 132:180736

TITLE: Procedure for the complexation of retinol with

cyclodextrins

INVENTOR(S): Regiert, Marlies; Moldenhauer, Jens-Peter

PATENT ASSIGNEE(S): Wacker-Chemie G.m.b.H., Germany

SOURCE: Ger., 6 pp.
CODEN: GWXXAW

DOCUMENT TYPE: Patent LANGUAGE: German

LANGUAGE: GEFAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19847633	C1	20000302	DE 1998-19847633	19981015
PRIORITY APPLN. INFO.:			DE 1998-19847633	19981015
an a management for the	2220311	ation of a s	table retinol/y-CD com	olev in

AB A procedure for the production of a stable retinol/ γ -CD complex, in which retinol is complexed with γ -CD in an aqueous solution, is characterized by complexation of retinol in the form of a polysorbate solution

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2000:56520 HCAPLUS

132:313521 DOCUMENT NUMBER:

Stabilization of retinol with .gamma .-TITLE:

cyclodextrin

Wimmer, T.; Regiert, M.; Moldenhauer, J.-P. AUTHOR(S):

Wacker-Chemie GmbH, Burghausen, D-84489, Germany CORPORATE SOURCE: Proceedings of the International Symposium on SOURCE:

> Cyclodextrins, 9th, Santiago de Comostela, Spain, May 31-June 3, 1998 (1999), Meeting Date 1998, 407-410. Editor(s): Labandeira, J. J. Torres; Vila-Jato, J. L.

Kluwer Academic Publishers: Dordrecht, Neth.

CODEN: 68NHAE

Conference DOCUMENT TYPE: English LANGUAGE:

 β - And . gamma.-cyclodextrin inclusion compds. of

retinol were prepared under nitrogen atmospheric by known methods. Generally a molar ratio of 2: 1 (CD:retinol) was found. Comparative storage studies of different complexes and phys. mixts. with lactose were performed using day light and UV radiation. The best stabilization was obtained using . gamma.-cyclodextrin which leads to new potential uses

for γ -CD also in health care applications.

REFERENCE COUNT: THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS 6 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN L5

1998:653668 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 129:265197

Complexes of .gamma.-cyclodextrin TITLE:

and retinol or retinol derivatives, their manufacture

APPLICATION NO.

DATE

and .use

Moldenhauer, Jens-Peter; Regiert, Marlies; INVENTOR(S):

DATE

Wimmer, Thomas

Wacker-Chemie G.m.b.H., Germany PATENT ASSIGNEE(S):

KIND

Eur. Pat. Appl., 8 pp. SOURCE:

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

									-						_			
	EP	8671	75			A1	19	98093	0 1	EP	1998-	1049	84		1	9980	319	
	EP	8671	75			B1	20	00080	9									
		R:	AT,	BE,	CH,	DE,	DK, H	ES, FR	, GB,	GR	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	•
			ΙE,	SI,	LT,	LV,	FI, F	20										
	DE	1971	3092			A1	19	98100	1 1	DE	1997-	1971	3092		1	9970	327	
	JP	1027	9504			Α	19	98102	0	JP	1998-	3920	3		1	9980	220	
	JP	3010	435			B2	20	00022	1									
	CA	2233	108			C	19	98092	7 (CA	1998-	2233	108		. 1	9980	320	
	CA	2233	108			A1	19	98092	7									
		5985				A	19	99111	6 t	US	1998-	4534	2		1	9980	320	
	HU	9800	688		•	A2	19	99020	1 1	HU	1998-	883			1	9980	327	
PRIOF											1997-							•
AB	For	rmati	on of	f ind	clus	ion d	compde	s. of	retino	ol,	reti	nol	deri	vs.,	or	reti	noic	
	aci	ld wi	th .	gamma	ac	yclo	dextri	n pro	tects	th	e ret	inoi	ds .					
	fro	xo m	idat	ion d	or U	V-A-:	induce	ed pho	tolys:	is (during	g st	orage	e. :	Thes	e ind	clusion	
									spond:									
	сус	lode	xtri	n, ai	nd a:	re us	seful	in an	ti-ag:	ing	cosmo	etic	s and	ď				
									, 109	_								
	_								mL d	_				heate	ed t	0		
	_								ed wit				•					
									empera		_				com	pound	d was	
																	ed dist	illed
	_		_									·	_					

water 650, .gamma.-cyclodextrin 100, macadamia nut oil 190, jojoba oil 30, avocado oil 20, and .gamma.-

cyclodextrin complex containing 9.8% retinol 10 weight parts.

REFERENCE COUNT:

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:673021 HCAPLUS

DOCUMENT NUMBER: 127:298554

TITLE: Stabilization and dispersion of plant oils containing

polyunsaturated fatty acid residues by complexation

with .gamma.-cyclodextrin

INVENTOR(S): Wimmer, Thomas; Regiert, Marlies;

Moldenhauer, Jens-Peter

PATENT ASSIGNEE(S): Wacker-Chemie Gmbh, Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PAT	TENT NO.			KINE	DATE	APPLICATION NO.	DATE	
DE	19612658			A1	19971002	DE 1996-19612658	19960329	
CA	2246282			A1	19971009	CA 1997-2246282	19970327	
CA	2246282			C	20020924			
WO	9736972			A1	19971009	WO 1997-EP1581	19970327	
	W: CA,							
	RW: AT,	BE,	CH,	DE,	DK, ES, FI,	FR, GB, GR, IE, IT,		SE
EP	889944			A1	19990113	EP 1997-914318	19970327	
EP	889944			B1	19991222			
	R: BE,	CH,	DE,	FR,	GB, IT, LI			
JP	11506496			${f T}$	19990608	JP 1997-534924	19970327	
US	6025510			A	20000215	US 1998-142568	19980915	
PRIORIT	Y APPLN.	INFO	. :			DE 1996-19612658	A 19960329	
						WO 1997-EP1581	W 19970327	

Plant oils with a high content of polyunsatd. fatty acid-containing AB triglycerides are stabilized against autoxidn. by addition of .gamma .-cyclodextrin, which forms inclusion complexes with the oils. The oils are useful in skin care products and as a source of essential fatty acids in foods. Complexation of the oils with .gamma .cyclodextrin also promotes formation of stable oil-in-water emulsions. Thus, a complex was prepared by mixing 180.0 g evening primrose oil with a solution of 833.8 g .gamma.-cyclodextrin in 1945 mL distilled water at 45°, stirring for 30 h, cooling to room temperature, filtering, and drying; the yield of complex was 802.1 g. After 38 days storage at room temperature in daylight, the oil in the .gamma.cyclodextrin complex had a peroxide number of 113, compared to 159 and 251 for complexes with α - and β - cyclodextrin, resp., and remained odorless and colorless, whereas the latter 2 complexes were rancid and yellow.

L5 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:27189 HCAPLUS

DOCUMENT NUMBER: 126:176631

TITLE: Application of .gamma.-cyclodextrin

for the stabilization and/or dispersion of vegetable oils containing triglycerides of polyunsaturated acids

AUTHOR(S):

CORPORATE SOURCE:

Regiert, M.; Wimmer, T.; Moldenhauer, J.-P.

Wacker-Chemie GmbH, Munich, D-81737, Germany

Journal of Inclusion Phenomena and Molecular

Recognition in Chemistry (1996), 25(1-3), 213-216

CODEN: JIMCEN; ISSN: 0923-0750

PUBLISHER: Kluwer
DOCUMENT TYPE: Journal
LANGUAGE: English

To improve the storage stability of instable vegetable oils with a high content of polyunsatd. fatty acid triglycerides, these essential compds. can be complexed with native cyclodextrins. Only with γ -CD a nearly complete complexation of the oils was achieved as shown by complexation kinetics measurements. Storage trials of the insol. Cd-complexes followed by the determination of the peroxide value of the oils

indicated that the best stabilization against autoxide. is obtained with γ -CD. An addnl. benefit of the complexation of triglycerides of

polyunsatd. fatty acids with .gamma.-cyclodextrin is

the formation of stable dispersions of these oils in aqueous media.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
46.96 47.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION
CONTROL OF THE TOTAL
ENTRY SESSION
CONTROL OF TOTAL
ENTRY SESSION
CONTROL OF TOTAL
ENTRY SESSION
CONTROL OF TOTAL
CONTROL OF THE TOTAL
CONTRO

CA SUBSCRIBER PRICE ENTRY SESSION -9.36 -9.36

FILE 'STNGUIDE' ENTERED AT 20:57:38 ON 07 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> fil hcaplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.12 47.29 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY -9.36 CA SUBSCRIBER PRICE 0.00

FILE 'HCAPLUS' ENTERED AT 20:59:03 ON 07 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2007 VOL 146 ISS 7 FILE LAST UPDATED: 6 Feb 2007 (20070206/ED)

`c'*;

```
New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d 15 5 rn
     ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
L5
     60-33-3D
RN
     1314-13-2
RN
     1332-37-2
RN
     7585-39-9
RN
RN
     9006-65-9D
     10016-20-3D
RN
     12619-70-4
RN
     13463-67-7
RN
     14807-96-6
RN
     17465-86-0
RN
     31692-79-2
RN
     111092-72-9
RN
     153315-80-1
RN
     60-33-3
RN
     10016-20-3
RN
=> E "1314-13-2"/BI,RN 25
                    1314-12-1DP/BI
E1
              3
                    1314-12-1P/BI
E2
             42
         87120 --> 1314-13-2/BI
E3
                    1314-13-2/RN
E4
              0
                    1314-13-2D/BI
E5
            964
                    1314-13-2DP/BI
           186
E6
                    1314-13-2P/BI
E7
          7080
                    1314-15-4/BI
E8
           978
                    1314-15-4D/BI
            17
E9
                    1314-15-4P/BI
            93
E10
                    1314-18-7/BI
E11
           339
                    1314-18-7D/BI
E12
              1
                    1314-18-7P/BI
             38
E13
                    1314-20-1/BI
          7149
E14
                    1314-20-1D/BI
E15
           258
                    1314-20-1DP/BI
            42
E16
                    1314-20-1P/BI
            695
E17
                    1314-22-3/BI
E18
            536
                    1314-22-3D/BI
E19
              4
                    1314-22-3P/BI
E20
             44
                    1314-23-4/BI
E21
         95729
                    1314-23-4D/BI
          2458
E22
                    1314-23-4DP/BI
            372
E23
                    1314-23-4P/BI
           9017
E24
                    1314-24-5/BI
E25
            219
=> S E3 OR E5 OR E6 OR E7
         87120 1314-13-2/BI
            964 1314-13-2D/BI
            186 1314-13-2DP/BI
          7080 1314-13-2P/BI
          87120 1314-13-2/BI OR 1314-13-2D/BI OR 1314-13-2DP/BI OR 1314-13-2P/BI
L6
=> E "6-33-3"/BI,RN 25
                    5ZZNZTITFE2/BI
              1
E1
                    6/BI
        3844305
E2
              0 --> 6-33-3/BI
E3
```

```
6-33-3/RN
E4
              0
       1207883
                    60/BI
E5
                    60-00-4/BI
E6
         30875
                    60-00-4D/BI
          3937
E7
                    60-00-4DP/BI
           583
E8
          1266
                    60-00-4P/BI
E9
                    60-01-4/BI
E10
              1
                    60-01-5/BI
E11
          1188
                    60-01-5D/BI
E12
              8
                    60-01-5P/BI
E13
             29
            366
                    60-02-6/BI
E14
                    60-02-6P/BI
E15
              2
                    60-06-0/BI
E16
              1
              1
                    60-06-0P/BI
E17
E18
              2
                    60-08-2/BI
E19
              2
                    60-08-2P/BI
E20
                    60-09-3/BI
          1809
                    60-09-3D/BI
E21
           122
                    60-09-3DP/BI
E22
             51
                    60-09-3P/BI
E23
            145
E24
          1911
                    60-10-6/BI
                    60-10-6D/BI
E25
            234
     "60-33-3"/BI,RN 25
E1
            392
                    60-32-2P/BI
E2
                    60-32-8/BI
              1
         37426 --> 60-33-3/BI
E3
                    60-33-3/RN
E4
              0
E5
          1559
                    60-33-3D/BI
E6
           227
                    60-33-3DP/BI
          1275
                    60-33-3P/BI
E7
E8
          3618.
                    60-34-4/BI
E9
                    60-34-4D/BI
             85
E10
             28
                    60-34-4DP/BI
                    60-34-4P/BI
E11
            115
E12
          6427
                    60-35-5/BI
E13
            307
                    60-35-5D/BI
E14
             94
                    60-35-5DP/BI
                    60-35-5P/BI
E15
            483
E16
             10
                    60-37-7/BI
                    60-37-7P/BI
             10
E17
                    60-38-8/BI
E18
            308
                    60-38-8D/BI
E19
              1
                    60-38-8P/BI
E20
             17
                    60-39-9/BI
E21
             28
E22
                    60-39-9D/BI
              1
                    60-39-9P/BI
E23
              4
E24
                    60-40-2/BI
            772
                    60-40-2D/BI
E25
              7
=> S E3 OR E5 OR E6 OR E7
         37426 60-33-3/BI
          1559 60-33-3D/BI
           227 60-33-3DP/BI
          1275 60-33-3P/BI
         37426 60-33-3/BI OR 60-33-3D/BI OR 60-33-3DP/BI OR 60-33-3P/BI
L7
=> E "1332-37-2"/BI,RN 25
            821
                    1332-29-2P/BI
E1
                    1332-30-5/BI
E2
             13
         21742 --> 1332-37-2/BI
E3
                    1332-37-2/RN
E4
              0
E5
                    1332-37-2D/BI
            308
```

Roy P. Issac

```
1332-37-2DP/BI
            56
E6
                    1332-37-2P/BI
          2118
E7
                    1332-40-7/BI
          1772
E8
            52
                    1332-40-7D/BI
E9
                    1332-40-7P/BI
            43
E10
                    1332-53-2/BI
E11
              5
                    1332-53-2D/BI
E12
             1
                    1332-57-6/BI
E13
             13
                    1332-58-7/BI
             1
E14
                    1332-59-8/BI
E15
                    1332-62-3/BI
             62
E16
                    1332-62-3P/BI
E17
              8
                    1332-63-4/BI
              1
E18
                    1332-63-4P/BI
              1
E19
                    1332-64-5/BI
            146
E20
                    1332-64-5D/BI
              1
E21
                    1332-64-5P/BI
E22
             19
                    1332-65-6/BI
           282
E23
                    1332-65-6D/BI
E24
              7
                    1332-65-6DP/BI
E25
              2
=> S E3 OR E5 OR E6 OR E7
         21742 1332-37-2/BI
            308 1332-37-2D/BI
             56 1332-37-2DP/BI
          2118 1332-37-2P/BI
         21742 1332-37-2/BI OR 1332-37-2D/BI OR 1332-37-2DP/BI OR 1332-37-2P/BI
L8
=> E "7585-39-9"/BI,RN 25
                    7585-37-7/BI
E1
              3
                    7585-37-7P/BI
E2
              1
         15147 --> 7585-39-9/BI
E3
                    7585-39-9/RN
E4
              0
                    7585-39-9D/BI
           5819
E5
                    7585-39-9DP/BI
          1032
E6
                    7585-39-9P/BI
E7
           1311
                    7585-41-3/BI
            142
E8
                    7585-41-3D/BI
              1
E9
                    7585-41-3DP/BI
E10
              1
                    7585-41-3P/BI
E11
              8
                    7585-47-9/BI
E12
             45
                    7585-47-9D/BI
E13
              1
                    7585-47-9P/BI
             20
E14
                    7585-48-0/BI
             22
E15
                    7585-48-0P/BI
              9
E16
                    7585-49-1/BI
E17
              2
                    7585-49-1P/BI
E18
              1
                    7585-50-4/BI
              1
E19
                    7585-52-6/BI
E20
              1
                    7585-52-6P/BI
              1
E21
                    7585-55-9/BI
E22
              1
                    7585-55-9P/BI
E23
              1
                    7585-56-0/BI
E24
              1
                    7585-56-0P/BI
              1
E25
=> S E3 OR E5 OR E6 OR E7
          15147 7585-39-9/BI
           5819 7585-39-9D/BI
           1032 7585-39-9DP/BI
           1311 7585-39-9P/BI
          15147 7585-39-9/BI OR 7585-39-9D/BI OR 7585-39-9DP/BI OR 7585-39-9P/BI
L9
=> E "9006-65-9"/BI,RN 25
```

Roy P. Issac Page 10

```
9006-55-7/BI
E1
                    9006-59-1/BI
E2
              1
          1771 --> 9006-65-9/BI
E3
                    9006-65-9/RN
E4
              0
                    9006-65-9D/BI
           218
E5
                    9006-65-9DP/BI
E6
                    9006-65-9P/BI
E7
              8
                    9006-66-0/BI
E8
              1
                    9006-66-0P/BI
E9
              1
                    9006-67-1/BI
             51
E10
                    9006-67-1D/BI
E11
              3
                    9006-67-1DP/BI
E12
              2
                    9006-67-1P/BI
E13
            27
                    9006-69-3/BI
E14
              1
             2
                    9006-70-6/BI
E15
                    9006-72-8/BI
E16
            45
                    9006-72-8D/BI
            15
E17
                    9006-72-8DP/BI
E18
              8
                    9006-72-8P/BI
E19
             20
                    9006-73-9/BI
E20
              9
                    9006-75-1/BI
E21
             16
                    9006-75-1D/BI
E22
              1
                    9006-75-1P/BI
E23
              1
                    9006-84-2/BI
E24
              1
                    9006-86-4/BI
E25
              9
=> S E3 OR E5 OR E6 OR E7
          1771 9006-65-9/BI
           218 9006-65-9D/BI
              4 9006-65-9DP/BI
              8 9006-65-9P/BI
          1771 9006-65-9/BI OR 9006-65-9D/BI OR 9006-65-9DP/BI OR 9006-65-9P/BI
L10
=> E "10016-20-3"/BI,RN 25
                    10016-19-0/BI
E1
              1
                    10016-19-0P/BI
E2
              1
          5210 --> 10016-20-3/BI
E3
                    10016-20-3/RN
E4
              0
                    10016-20-3D/BI
E5
          1118
                    10016-20-3DP/BI
           279
E6
                    10016-20-3P/BI
           453
E7
                    10016-26-9/BI
E8
            10
                    10016-26-9P/BI
E9
              1
                    10016-32-7/BI
E10
           203 ·
                    10016-32-7D/BI
E11
            41
                    10016-32-7DP/BI
E12
             11
                    10016-32-7P/BI
E13
             52
                    10016-36-1/BI
E14
              5
                    10016-36-1P/BI
E15
              2
E16
                    10016-41-8/BI
              1
                    10016-41-8P/BI
E17
              1
                    10016-42-9/BI
E18
              2
                    10016-42-9P/BI
E19
              2
E20
                    10016-52-1/BI
             45
E21
                    10016-52-1P/BI
             18
E22
                    10016-56-5/BI
              1
E23
                    10016-57-6/BI
              1
E24
                    10016-59-8/BI
              3
                    10016-59-8P/BI
E25
              3
=> S E3 OR E5 OR E6 OR E7
          5210 10016-20-3/BI
```

Roy P. Issac Page 11

1118 10016-20-3D/BI

```
279 10016-20-3DP/BI
           453 10016-20-3P/BI
          5211 10016-20-3/BI OR 10016-20-3D/BI OR 10016-20-3DP/BI OR 10016-20-3P/BI
L11
=> E "12619-70-4"/BI,RN 25
                    12619-68-0DP/BI
El
             1
                    12619-68-0P/BI
            25
E2
          5609 --> 12619-70-4/BI
E3
                    12619-70-4/RN
E4
              0
                    12619-70-4D/BI
          1505
E5
                    12619-70-4DP/BI
           244
E6
                    12619-70-4P/BI
           527
E7
                    12619-71-5/BI
E8
            64
                    12619-71-5D/BI
            10
E9
                    12619-71-5DP/BI
E10
              4
                    12619-71-5P/BI
E11
                    12619-72-6/BI
             9
E12
                    12619-72-6P/BI
E13
             3
                    12619-74-8/BI
             1
E14
                    12619-75-9/BI
E15
            10
                    12619-76-0/BI
E16
              7
                    12619-77-1/BI
E17
                    12619-78-2/BI
             7
E18
                    12619-80-6/BI
              5
E19
                    12619-81-7/BI
E20
             1
                    12619-82-8/BI
E21
              1
                    12619-83-9/BI
             3
E22
                    12619-84-0/BI
E23
              1
                    12619-85-1/BI
              3
E24
                    12619-86-2/BI
E25
           100
=> S E3 OR E5 OR E6 OR E7
          5609 12619-70-4/BI
          1505 12619-70-4D/BI
           244 12619-70-4DP/BI
           527 12619-70-4P/BI
          5609 12619-70-4/BI OR 12619-70-4D/BI OR 12619-70-4DP/BI OR 12619-70-4P/BI
L12
=> E "13463-67-7"/BI,RN 25
                    13463-65-5/BI
E1
              1
                    13463-65-5P/BI
E2
             1
        161050 --> 13463-67-7/BI
E3
                    13463-67-7/RN
E4
              0
                    13463-67-7D/BI
E5
          2449
E6
           530
                    13463-67-7DP/BI
                    13463-67-7P/BI
E7
         16054
                    13463-71-3/BI
E8
            18
                    13463-71-3D/BI
E9
             1
                    13463-71-3P/BI
            12
E10
                    13463-78-0/BI
E11
             1
                    13463-79-1/BI
E12
              1
             1
                    13463-80-4/BI
E13
                    13463-84-8/BI
E14
             1
                    13463-85-9/BI
E15
              1
                    13463-87-1/BI
              1
E16
                    13463-89-3/BI
              1
E17
                    13463-90-6/BI
E18
              1
                    13463-90-6P/BI
E19
              1
                    13463-91-7/BI
E20
              6
                    13463-91-7P/BI
E21
              4
                    13463-94-0/BI
E22
             56
                    13463-94-0P/BI
E23
             25
                    13463-96-2/BI
E24
              4
```

Roy P. Issac

```
13463-96-2P/BI
E25
=> S E3 OR E5 OR E6 OR E7
        161050 13463-67-7/BI
          2449 13463-67-7D/BI
           530 13463-67-7DP/BI
         16054 13463-67-7P/BI
        161050 13463-67-7/BI OR 13463-67-7D/BI OR 13463-67-7DP/BI OR 13463-67-7P/BI
L13
=> E "14807-96-6"/BI,RN 25
                    14807-82-0P/BI
E1
             1
E2
                    14807-84-2/BI
         27802 --> 14807-96-6/BI
E3
                    14807-96-6/RN
E4
              0
E5
                    14807-96-6D/BI
           137
                    14807-96-6DP/BI
E6
            45
E7
           783
                    14807-96-6P/BI
                    14807-97-7/BI
E8
                    148070-00-2/BI
E9
             1
E10
                    148070-00-2P/BI
             1
                    148070-01-3/BI
E11
             1
E12
                    148070-01-3P/BI
                    148070-02-4/BI
E13
             1
             1
                    148070-02-4P/BI
E14
                    148070-03-5/BI
E15
             1
                    148070-03-5P/BI
E16
             1
                    148070-04-6/BI
E17
             1
E18
                    148070-04-6P/BI
                    148070-05-7/BI
E19
             1
E20
                    148070-05-7P/BI
                    148070-06-8/BI
             1
E21
                    148070-06-8P/BI
E22
             1
                    148070-07-9/BI
E23
             1
                    148070-07-9P/BI
E24
             1
                    148070-08-0/BI
E25
=> S E3 OR E5 OR E6 OR E7
         27802 14807-96-6/BI
           137 14807-96-6D/BI
            45 14807-96-6DP/BI
           783 14807-96-6P/BI
         27802 14807-96-6/BI OR 14807-96-6D/BI OR 14807-96-6DP/BI OR 14807-96-6P/BI
L14
=> E "17465-86-0"/BI,RN 25
                    17465-74-6/BI
E1
             1
                    17465-74-6P/BI
E2
             1
          4128 --> 17465-86-0/BI
E3
E4
                    17465-86-0/RN
             0
E5
                   17465-86-0D/BI
          1019
           228
                   17465-86-0DP/BI
E6
           395
                    17465-86-0P/BI
E7
E8
                   17465-87-1/BI
             7
E9
             5
                   17465-87-1P/BI
                    17465-88-2/BI
E10
E11
                    17465-88-2P/BI
             1
E12
                    17465-91-7/BI
             1
E13
                   17465-91-7P/BI
             1
                   17465-92-8/BI
E14
             1
E15
                    17465-92-8P/BI
E16
                   17465-93-9/BI
             1
E17
                    17465-93-9P/BI
             1
                   17.465-94-0/BI
E18
             2
E19
                    17465-94-0P/BI
             2
```

Roy P. Issac

```
17465-95-1/BI
E20
             3
                   17465-95-1P/BI
E21
             1
                    17465-96-2/BI
E22
                   17465-96-2P/BI
E23
             1
                    17465-97-3/BI
             1
E24
                    17465-97-3P/BI
E25
             1
=> S E3 OR E5 OR E6 OR E7
          4128 17465-86-0/BI
          1019 17465-86-0D/BI
           228 17465-86-0DP/BI
           395 17465-86-0P/BI
          4128 17465-86-0/BI OR 17465-86-0D/BI OR 17465-86-0DP/BI OR 17465-86-0P/BI
L15
=> E "31692-79-2"/BI,RN 25
                   31692-72-5P/BI
             1
E1
                    31692-75-8/BI
E2
             1
          1553 --> 31692-79-2/BI
E3
                    31692-79-2/RN
E4
             0
                    31692-79-2D/BI
E5
           266
                   31692-79-2DP/BI
           192
E6
                    31692-79-2P/BI
E7
           279
                    31692-81-6/BI
E8
             2
                   31692-85-0/BI
E9
           247
                   31692-85-0D/BI
E10
             1
                   31692-85-0P/BI
E11
                   31692-86-1/BI
            11
E12
                   31692-86-1D/BI
E13
             1
                   31692-86-1P/BI
E14
             1
                    31692-87-2/BI
E15
             1
                    31692-88-3/BI
             1
E16
                    31692-89-4/BI
E17
             2
                   31692-90-7/BI
E18
             1
             1
                   31692-92-9/BI
E19
                   31692-92-9P/BI
E20
             1
                   31692-93-0/BI
            11
E21
E22
                    31692-93-0P/BI
             2
                    316920-00-0/BI
E23
             1
                    316920-01-1/BI
E24
             1
             1
                    316920-02-2/BI
E25
=> S E3 OR E5 OR E6 OR E7
          1553 31692-79-2/BI
           266 31692-79-2D/BI
           192 31692-79-2DP/BI
           279 31692-79-2P/BI
          1553 31692-79-2/BI OR 31692-79-2D/BI OR 31692-79-2DP/BI OR 31692-79-2P/BI
L16
=> E "111092-72-9"/BI,RN 25
                    111092-69-4/BI
E1
             1
                    111092-71-8/BI
E2
             2
             7 --> 111092-72-9/BI
E3
                    111092-72-9/RN
E4
             0
                    111092-73-0/BI
E5
                    111092-73-0D/BI
E6
             2
             1
                    111092-74-1/BI
E7
                    111092-75-2/BI
E8
             1
                    111092-76-3/BI
             1.
E9
                    111092-77-4/BI
             1
E10
                    111092-78-5/BI
E11
             1
                    111092-79-6/BI
E12
             1
                    111092-80-9/BI
E13
                    111092-81-0/BI
E14
             2
```

Roy P. Issac Page 14

```
111092-82-1/BI
E15
                    111092-83-2/BI
             1
E16
                    111092-84-3/BI
             1
E17
                    111092-85-4/BI
             1.
E18
                    111092-86-5/BI
             1
E19
                    111092-87-6/BI
E20
             1
                    111092-88-7/BI
             1
E21
                    111092-89-8/BI
             1
E22
                    111092-90-1/BI
             1
E23
                    111092-91-2/BI
E24
             1
                    111092-92-3/BI
             1
E25
=> S E3
             7 111092-72-9/BI
L17
=> E "153315-80-1"/BI,RN 25
                    153315-79-8/BI
E1
             2
                    153315-79-8P/BI
E2
          1411 --> 153315-80-1/BI
E3
                    153315-80-1/RN
E4
             0
                    153315-80-1D/BI
E5
            77
                    153315-80-1DP/BI
E6
            59
                    153315-80-1P/BI
E7
           606
                    153315-81-2/BI
E8
           378
                    153315-81-2D/BI
E9
            15
                    153315-81-2DP/BI
E10
            13
E11
            58
                    153315-81-2P/BI
                    153315-82-3/BI
E12
             2
                    153315-82-3P/BI
E13
             1
                    153315-83-4/BI
E14
                    153315-84-5/BI
E15
              1
             · 1
                    153315-85-6/BI
E16
                    153315-86-7/BI
             1
E17
                    153315-87-8/BI
             1
E18
                    153315-88-9/BI
             1
E19
             1
                    153315-89-0/BI
E20
                    153315-89-0P/BI
E21
              1
                    153315-90-3/BI
E22
                    153315-90-3P/BI
E23
                    153315-91-4/BI
E24
             1
                    153315-92-5/BI
E25
             1
=> S E3 OR E5 OR E6 OR E7
          1411 153315-80-1/BI
            77 153315-80-1D/BI
            59 153315-80-1DP/BI
           606 153315-80-1P/BI
          1411 153315-80-1/BI OR 153315-80-1D/BI OR 153315-80-1DP/BI OR 153315-80-1P/BI
L18
=> E "10016-20-3"/BI,RN 25
                    10016-19-0/BI
El
              1
                    10016-19-0P/BI
E2
              1
E3
          5210 --> 10016-20-3/BI
                    10016-20-3/RN
E4
              0
                    10016-20-3D/BI
E5
          1118
E6
                    10016-20-3DP/BI
           279
                    10016-20-3P/BI
           453
E7
E8
            10
                    10016-26-9/BI
E9
                    10016-26-9P/BI
E10
                    10016-32-7/BI
           203
E11
                    10016-32-7D/BI
            41
E12
                    10016-32-7DP/BI
            11
E13
                    10016-32-7P/BI
            52
```

Roy P. Issac Page 15

```
10016-36-1/BI
E14
                   10016-36-1P/BI
E15
                   10016-41-8/BI
             1
E16
                   10016-41-8P/BI
             1
E17
                   10016-42-9/BI
E18
                   10016-42-9P/BI
             2
E19
            45
                   10016-52-1/BI
E20
                   10016-52-1P/BI
E21
            18
            1
                   10016-56-5/BI
E22
                   10016-57-6/BI
           1
E23
                   10016-59-8/BI
             3
E24
                   10016-59-8P/BI
E25
             3
=> S E3 OR E5 OR E6 OR E7
          5210 10016-20-3/BI
          1118 10016-20-3D/BI
           279 10016-20-3DP/BI
           453 10016-20-3P/BI
          5211 10016-20-3/BI OR 10016-20-3D/BI OR 10016-20-3DP/BI OR 10016-20-3P/BI
L19
=> d his
     (FILE 'HOME' ENTERED AT 20:54:10 ON 07 FEB 2007)
     FILE 'HCAPLUS' ENTERED AT 20:54:39 ON 07 FEB 2007
                E US2003-712703/PN 25
                E REGIERT M/AU 25
             20 S (E3 OR E4)
Ll
                E KUPKA M/AU 25
             39 S (E3 OR E4 OR E9 OR E10)
L2
                E CYCLODEXTRIN+ALL/CT
         312049 S (CYCLODEXTRIN OR "CHEMICAL COMPOUNDS" OR "ORGANIC COMPOUNDS"
L3
             56 S L1-L2
L4
             12 S L4 AND L3
L5
     FILE 'STNGUIDE' ENTERED AT 20:57:38 ON 07 FEB 2007
     FILE 'HCAPLUS' ENTERED AT 20:59:03 ON 07 FEB 2007
                E "1314-13-2"/BI,RN 25
          87120 S E3 OR E5 OR E6 OR E7
L6
                E "6-33-3"/BI,RN 25
                E "60-33-3"/BI,RN 25
          37426 S E3 OR E5 OR E6 OR E7
L7
                E "1332-37-2"/BI,RN 25
          21742 S E3 OR E5 OR E6 OR E7
\Gamma8
                E "7585-39-9"/BI,RN 25
          15147 S E3 OR E5 OR E6 OR E7
L9
                E "9006-65-9"/BI,RN 25
           1771 S E3 OR E5 OR E6 OR E7
L10
                E "10016-20-3"/BI,RN 25
           5211 S E3 OR E5 OR E6 OR E7
L11
                E "12619-70-4"/BI,RN 25
           5609 S E3 OR E5 OR E6 OR E7
L12
                E "13463-67-7"/BI,RN 25
         161050 S E3 OR E5 OR E6 OR E7
L13
                E "14807-96-6"/BI,RN 25
          27802 S E3 OR E5 OR E6 OR E7
L14
                E "17465-86-0"/BI,RN 25
           4128 S E3 OR E5 OR E6 OR E7
L15
                E "31692-79-2"/BI,RN 25
           1553 S E3 OR E5 OR E6 OR E7
L16
                E "111092-72-9"/BI,RN 25
              7 S E3
L17
```

Roy P. Issac

E "153315-80-1"/BI,RN 25

L18 1411 S E3 OR E5 OR E6 OR E7

E "10016-20-3"/BI,RN 25

L19 5211 S E3 OR E5 OR E6 OR E7

=> s 16-119

L20 331859 (L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)

=> s 120 and 15

L21 10 L20 AND L5

=> d ti 1-10

- L21 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Solvent-free dispersions of 1:1 or 2:1 cyclodextrin-perfume complexes
- L21 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Stabilizing linoleic acid by complexation with α -cyclodextrin
- L21 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Light stability of vitamin E by encapsulation in .gamma.-cyclodextrin
- L21 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Cosmetic composition comprising a complex of cyclodextrin and vitamin F
- L21 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Cyclodextrins: an other tool for encapsulation
- L21 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Procedure for the complexation of retinol with cyclodextrins
- L21 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Stabilization of retinol with .gamma.-cyclodextrin
- L21 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Complexes of .gamma.-cyclodextrin and retinol or retinol derivatives, their manufacture and use
- L21 . ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Stabilization and dispersion of plant oils containing polyunsaturated fatty acid residues by complexation with .gamma. cyclodextrin
- L21 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
- TI Application of .gamma.-cyclodextrin for the stabilization and/or dispersion of vegetable oils containing triglycerides of polyunsaturated acids

=> d l21 4 ibib abs hitstr

L21 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:402912 HCAPLUS

DOCUMENT NUMBER: 140:412001

TITLE: Cosmetic composition comprising a complex of

cyclodextrin and vitamin F

INVENTOR(S): Regiert, Marlies; Kupka, Michaela

PATENT ASSIGNEE(S): Wacker-Chemie GmbH, Germany

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	EP 1419761	A1 B1	20051019	EP 2003-26137	20031113
	IE, SI, LT, DE 10253042	LV, FI A1	7, RO, MK, CY 20040603	B, GR, IT, LI, LU, NL, S T, AL, TR, BG, CZ, EE, H DE 2002-10253042	IU, SK 20021114
	US 2004096413	A1	20040520	KR 2003-77579 US 2003-712703	20031112
DDTC	JP 2004161775 RITY APPLN. INFO.:		20040610	JP 2003-385675 DE 2002-10253042 A	
AB	The invention conce	rns cos	metic and de	ermatol. compns. that co	
	complexes of vitami	n F wit	th α , β , or .	gamma ne formulations are: sil	icone
	oils, moisturizers,	skin c	are substanc	es, gelation agents, ba	actericides,
	antioxidants, sunsc	reens,	emulsifiers,	pigments, tanning ager	nts, etc.
	Thus 0.1 mol α - cyc 0.1 mol linolic aci	d was a	in was mixed idded, homoge	enized and stirred for 3	30 h at RT and
	for 8 h at 70°C; th	e produ	ict was dispe	ersed in water, filtered	ł,
	washed and dried un cyclodextrin-linoli			oosition contained (weigh	ght/weight%):α-
	cyclodextrin-a-toco	pherol	complex 1.5;	octyl palmitate 2.5;	
	octyl stearate 3.5;	polygl	ycerol-2 ses	squiisostearate 2.0; cyc	clomethicone,
	dimethiconol 3.0; I glycoside, cyclomet			2.0; octyl dimethicone e	etnoxy
	polymethylsilsesqui	oxane 1	0; zinc oxi	de 2.0; glycerin 2.0; n	nethylparaben
T.M.	0.1; sodium chlorid 60-33-3D, Linolic a			- gyglodeytrin	
IT	1314-13-2, Zinc oxi	de, bio	ological stud	lies 1332-37-2,	
	Iron oxide, biologi	cal stu	dies 7585-39	9-9, β-	
	Cyclodextrin 9006-6 10016-20-3D, α- Cyc				
	acid 12619-70-4, Cy				
	Titanium dioxide, b	iologic	cal studies 1		
	biological studies Cyclodextrin 31692-				
	111092-72-9 153315-) I MCCIII COIIO I		
	RL: COS (Cosmetic u (cosmetic compos vitamin F)	se); Bl	OL (Biologic comprising a	cal study); USES (Uses) complex of cyclodextrin	n and
RN	60-33-3 HCAPLUS		,		
CN	9,12-Octadecadienoi	c acid	(9Z, 12Z) - (9Z, 12Z)	OCI) (CA INDEX NAME)	

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 1314-13-2 HCAPLUS CN Zinc oxide (ZnO) (9CI) (CA INDEX NAME)

0=- Zn

RN 1332-37-2 HCAPLUS

CN Iron oxide (8CI, 9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN. 7585-39-9 HCAPLUS


CN β -Cyclodextrin (8CI, 9CI). (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 9006-65-9 HCAPLUS

CN Dimethicone (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

.

55 B

10/712,703>07/02/2007

RN 12619-70-4 HCAPLUS

CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 13463-67-7 HCAPLUS

CN Titanium oxide (TiO2) (8CI, 9CI) (CA INDEX NAME)

o = Ti = o

RN 14807-96-6 HCAPLUS CN Talc (Mg3H2(SiO3)4) (9CI) (CA INDEX NAME)

О || но-si-он

●3/4 Mg

RN 17465-86-0 HCAPLUS CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Page 20

RN 31692-79-2 HCAPLUS CN Poly[oxy(dimethylsilylene)], α -hydro- ω -hydroxy- (8CI, 9CI) (CA INDEX NAME)

RN 111092-72-9 HCAPLUS CN 1,2,3-Propanetriol, homopolymer, isooctadecanoate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 30399-84-9 CMF C18 H36 O2 CCI IDS

CM 2

CRN 25618-55-7 CMF (C3 H8 O3)x CCI PMS

CM 3

CRN 56-81-5 CMF C3 H8 O3

RN 153315-80-1 HCAPLUS CN Poly[(1,3-dimethyl-1,3:1,3-disiloxanediylidene)-1,3-bis(oxy)] (9CI) (CA INDEX NAME)

IT 60-33-3, Linolic acid, biological studies 10016-20-3, $\alpha\text{-}$ Cyclodextrin

RL: COS (Cosmetic use); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)

(cosmetic composition comprising a complex of cyclodextrin and vitamin F)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stng COST IN U.S. DOLLARS SINCE FILE TOTAL **SESSION ENTRY** FULL ESTIMATED COST 40.21 87.50 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL **SESSION** ENTRY CA SUBSCRIBER PRICE -0.78 -10.14

FILE 'STNGUIDE' ENTERED AT 21:06:31 ON 07 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> d his

(FILE 'HOME' ENTERED AT 20:54:10 ON 07 FEB 2007)

FILE 'HCAPLUS' ENTERED AT 20:54:39 ON 07 FEB 2007

E US2003-712703/PN 25

E REGIERT M/AU 25

L1 20 S (E3 OR E4)

E KUPKA M/AU 25

L2 39 S (E3 OR E4 OR E9 OR E10)

E CYCLODEXTRIN+ALL/CT

L3 312049 S (CYCLODEXTRIN OR "CHEMICAL COMPOUNDS" OR "ORGANIC COMPOUNDS"

L4 56 S L1-L2

L5 12 S L4 AND L3

FILE 'STNGUIDE' ENTERED AT 20:57:38 ON 07 FEB 2007

FILE 'HCAPLUS' ENTERED AT 20:59:03 ON 07 FEB 2007 E "1314-13-2"/BI,RN 25

L6	87120	E	E3 OR E5 OR E6 OR E7 "6-33-3"/BI,RN 25
		E	"60-33-3"/BI,RN 25
L7	37426	S	E3 OR E5 OR E6 OR E7
		E	"1332-37-2"/BI,RN 25
L8	21742	S	E3 OR E5 OR E6 OR E7
		E	"7585-39-9"/BI,RN 25
L9	15147	S	E3 OR E5 OR E6 OR E7
		E	"9006-65-9"/BI,RN 25
L10	1771	S	E3 OR E5 OR E6 OR E7
		E	"10016-20-3"/BI,RN 25
L11	5211	S	E3 OR E5 OR E6 OR E7
		E	"12619-70-4"/BI,RN 25
L12	5609	S	E3 OR E5 OR E6 OR E7
		E	"13463-67-7"/BI,RN 25
L13	161050	S	E3 OR E5 OR E6 OR E7
		E	"14807-96-6"/BI,RN 25
L14	27802		E3 OR E5 OR E6 OR E7
		E	"17465-86-0"/BI,RN 25
L15	4128	S	E3 OR E5 OR E6 OR E7
		E	"31692-79-2"/BI,RN 25
L16	1553	S	E3 OR E5 OR E6 OR E7
		E	"111092-72-9"/BI,RN 25
L17	7	S	E3
		E	"153315-80-1"/BI,RN 25
L18	1411	S	E3 OR E5 OR E6 OR E7
		E	"10016-20-3"/BI,RN 25
L19	5211	S	E3 OR E5 OR E6 OR E7
L20	331859		
L21			L20 AND L5

FILE 'STNGUIDE' ENTERED AT 21:06:31 ON 07 FEB 2007

=> fil stng
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE
TOTAL
ENTRY
SESSION
CA SUBSCRIBER PRICE

0.00 -10.14

FILE 'STNGUIDE' ENTERED AT 21:07:25 ON 07 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> fil hcaplus COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.36	87.98
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.14

FILE 'HCAPLUS' ENTERED AT 21:11:05 ON 07 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS) Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2007 VOL 146 ISS 7 FILE LAST UPDATED: 6 Feb 2007 (20070206/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19 or 111 or 115

L22 17303 L9 OR L11 OR L15

=> s 17 or 117 or 118

L23 38840 L7 OR L17 OR L18

=> s 122 and 123

L24 62 L22 AND L23

=> S L24 AND 1800<=PY<=2002

22869364 1800<=PY<=2002

L25 40 L24 AND 1800<=PY<=2002

=> d 125 ibib abs hitstr

L25 ANSWER 1 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:554493 HCAPLUS

DOCUMENT NUMBER: 140:258803

TITLE: Quality study of volatile oil enclosed with

β-cyclodextrin in Naokangling capsule

AUTHOR(S): Wang, Yan; Zhou, Liling; Liu, Qingfei; Qiu, Meixian;

Liang, Shuyan

CORPORATE SOURCE: Guangzhou University of TCM, Canton, 510405, Peop.

Rep. China

SOURCE: Guangzhou Zhongyiyao Daxue Xuebao (2002),

19(4), 311-313

CODEN: GZDXFQ; ISSN: 1007-3213

PUBLISHER: Guangzhou Zhongyiyao Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal LANGUAGE: Chinese

AB Study the quality of volatile oil enclosed with β -cyclodextrin (β -CD) in Naokangling capsule. The quality of the volatile oil in Naokangling capsule before and after enclosure was examined by thin layer chromatog., UV and gas chromatog.-mass spectrometry. The inclusion of volatile oil and β -cyclodextrin was steady, and the quality of volatile oil was not changed before and after enclosure. The process of enclosure with β -CD can keep the active components of the volatile oil in Naokangling capsule.

IT 60-33-3, Linoleic acid, biological studies
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quality study of volatile oil enclosed with cyclodextrin in Naokangling capsule)

10/712,703>07/02/2007

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$_{\rm HO_2C}$$
 (CH₂) 7 $_{\rm Z}$ $_{\rm Z}$ (CH₂) 4 $_{\rm Me}$

IT 7585-39-9, β -Cyclodextrin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (quality study of volatile oil enclosed with cyclodextrin in Naokangling capsule)

RN 7585-39-9 HCAPLUS


CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 2-A



=> d 125 ibib abs hitstr 2-5

L25 ANSWER 2 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:869813 HCAPLUS

DOCUMENT NUMBER: 138:88882

TITLE:

Pasting property differences of commercial and

isolated rice starch with added lipids and

β-cyclodextrin

AUTHOR(S):

Liang, Xiaoming; King, Joan M.; Shih, Fred F.

CORPORATE SOURCE:

Department of Food Science, Louisiana State University

Agricultural Center, Baton Rouge, LA, 70803, USA

SOURCE:

Cereal Chemistry (2002), 79(6), 812-818

CODEN: CECHAF; ISSN: 0009-0352

PUBLISHER:

American Association of Cereal Chemists

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Lipids are known to generally affect starch properties but the effects of AB lipid structure and β -cyclodextrin (β -CD) on different starches has not been investigated. This study compared the effects of lipids and β -CD on pasting properties of isolated rice starch with com. rice starch. Flour was defatted by Soxhlet extraction and deproteinated by alkaline protease digestion. Fatty acids, monopalmitin (MP), tripalmitin, lysophosphatidylcholine (LC), lysophophatidylethanolamine (LE), each added at 0.2 and 0.6% (starch db), and β -CD added at 2 and 6% (starch db) were tested. Pasting temperature (PT) increased with added phospholipid, particularly in the com. starch, while all lipids except tripalmitin increased final viscosity (FV) and total setback (TSB). Breakdown (BKD) was mainly affected and increased by up to 39 RVU for fatty acids while decreasing by up to 80 RVU for other lipids in both starches. TSB doubled by the addition of 0.6% MP but decreased to one-third by 0.6% LE or LC. Addition of β -CD decreased min. viscosity (MV) and FV while increasing BKD in the isolate but decreased TSB in com. starch.

60-33-3, Linoleic acid, biological studies 7585-39-9, IT β-Cyclodextrin


RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process)

(pasting property differences of com. and isolated rice starch with added lipids and β -cyclodextrin)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME) CN

Double bond geometry as shown.




7585-39-9 HCAPLUS RN

β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:846052 HCAPLUS

DOCUMENT NUMBER: 138:69780

TITLE: Increased Staphylococcus-killing activity of an

antimicrobial peptide, lactoferricin B, with

minocycline and monoacylglycerol

AUTHOR(S): Wakabayashi, Hiroyuki; Teraguchi, Susumu; Tamura,

Yoshitaka

CORPORATE SOURCE: Nutritional Science Laboratory, Morinaga Milk Industry

Co., Ltd., Kanagawa, 228-8583, Japan

SOURCE: Bioscience, Biotechnology, and Biochemistry (

2002), 66(10), 2161-2167

CODEN: BBBIEJ; ISSN: 0916-8451

PUBLISHER: Japan Society for Bioscience, Biotechnology, and

Agrochemistry

DOCUMENT TYPE: Journal LANGUAGE: English

This study aimed to find antibiotics or other compds. that could increase the antimicrobial activity of an antimicrobial peptide, lactoferricin B (LFcin B), against Staphylococcus aureus, including antibiotic-resistant strains. Among conventional antibiotics, minocycline increased the bactericidal activity of LFcin B against S. aureus, but methicillin, ceftizoxime, and sulfamethoxazole-trimethoprim did not have such an

effects against three antibiotic-resistant strains of S. aureus, according to result of checkerboard anal. Screening of 33 compds., including acids and salts, alcs., amino acids, proteins and peptides, sugar, and lipids, showed that medium-chain monoacyl-glycerols increased the bactericidal activity of LFcin B against three S. aureus strains. The short-term killing test in water and the killing curve test in growing cultures showed that a combination of LFcin B and monolaurin (a monoacylglycerol with a 12-carbon acyl chain) killed S. aureus more rapidly than either agent alone. These findings may be helpful in the application of antimicrobial peptides in medical or other situations.

IT 60-33-3, Linoleic acid, biological studies 7585-39-9,
β-Cyclodextrin

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antimicrobial peptide lactoferricin B combined with antibiotics or chemical compds. activity against Staphylococcus aureus)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A

DATE

OH

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 27 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN L25

2002:695819 HCAPLUS ACCESSION NUMBER:

137:222086 DOCUMENT NUMBER:

Compositions comprising an o/w emulsion containing TITLE:

conjugated linoleic acid

Remmereit, Jan; Klaveness, Jo INVENTOR(S):

Natural Asa, Norway; Cockbain, Julian PATENT ASSIGNEE(S):

PCT Int. Appl., 29 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
DATE APPLICATION NO.
    PATENT NO.
                        KIND
                                           WO 2002-GB996
                         A1
                               20020912
                                                                 20020307 <--
    WO 2002070014
                         A8
                               20031127
    WO 2002070014
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
                               20020912
                                           CA 2002-2455226
                                                                 20020307 <--
    CA 2455226
                         A1
                                           EP 2002-704908
    EP 1372728
                         A1
                               20040102
                                                                  20020307
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                           US 2003-471049
                               20040422
                                                                  20031222
    US 2004077724
                         A1
PRIORITY APPLN. INFO.:
                                           GB 2001-5622
                                                              A 20010307
                                           WO 2002-GB996
                                                               W 20020307
```

- The present invention provides a method of treatment of a human or AB non-human (e.g. mammalian, avian or reptilian) animal subject by the parenteral administration of a lipophilic pharmaceutical agent, the improvement comprising administering said pharmaceutical agent in an oil-in-water emulsion containing a conjugated linoleic acid (CLA) or a physiol. tolerable derivative thereof. A mixture of 10 g CLA triglyceride (produced by reacting CLA with glycerol), 1.0 g purified egg phospholipid, 50 mg sodium stearate and 5 g α -tocopherol was finely dispersed. A mixture of 100 mL water containing 2.5 g glycerol and 0.05 mmol NaOH was added to the CLA mixture during stirring at room temperature. The mixture was homogenized in a high pressure homogenator and the final emulsion filled into vials and heat-sterilized.
- 60-33-3D, Linoleic acid, conjugates 17465-86-0, IT γ -Cyclodextrin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. comprising o/w emulsion containing conjugated linoleic acid)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME) CN

Roy P. Issac Page 30 Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2002:551533 HCAPLUS

DOCUMENT NUMBER:

137:114518

TITLE:

Skin sanitizing compositions

INVENTOR(S):

Sine, Mark Richard; Wei, Karl Shiqing; Jakubovic,

David Andrew; Thomas, Cheyne P.; Dodd, Michael Thomas;

Putman, Christopher Dean

PATENT ASSIGNEE(S):

The Procter & Gamble Company, USA

SOURCE:

U.S., 14 pp., Cont. of U.S. Ser. No. 321,291.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423329 PRIORITY APPLN. INFO.:	B1	20020723	US 2000-504286 US 1999-249717 US 1999-120098P	20000215 < A2 19990212 P 19990216
			US 1999-321291	A2 19990527

The present invention relates to compns. and methods of sanitizing and moisturizing skin surfaces. A sanitizing and moisturizing gel contained EtOH 55, isopropanol 3, Biowax-754 0.4, Carbopol Ultrez-10 0.3, Carbowax

10/712,703>07/02/2007

PEG-200 0.26, propylene glycol 0.02, aminomethylpropanol 0.15, and perfume 0.1%, and water qs.
IT 60-33-3D, 9,12-Octadecadienoic acid (9Z,12Z)-, lanolin esters 7585-39-9, β-Cyclodextrin 7585-39-9D, β-Cyclodextrin, alkyl ethers 10016-20-3, α-Cyclodextrin 10016-20-3D, α-Cyclodextrin, alkyl ethers RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (skin sanitizing compns.)
RN 60-33-3 HCAPLUS
9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

$$_{\text{HO}_2\text{C}}$$
 (CH₂) 7 $_{\text{Z}}$ $_{\text{Me}}$

RN 7585-39-9 HCAPLUS CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

OH H OH HO RS R R H OH HO Η Н OH OH HO HO OH H OH HO R OH ОН HO R OH HO H



PAGE 1-A

RN 7585-39-9 HCAPLUS

Roy P. Issac

CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

Roy P. Issac

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 125 ibib abs hitstr 6-40

L25 ANSWER 6 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

56

ACCESSION NUMBER: 2002:369910 HCAPLUS

DOCUMENT NUMBER:

137:190835

TITLE:

Separation and first structure elucidation of cremophor EL-components by hyphenated capillary

electrophoresis and delayed extraction-matrix assisted

laser desorption/ionization-time of flight-mass

spectrometry

AUTHOR(S): Meyer, Thomas; Waidelich, Dietmar; Frahm, August

Wilhelm

CORPORATE SOURCE: Albert-Ludwigs-University, Freiburg im Breisgau,

D-79104, Germany

SOURCE: Electrophoresis (2002), 23(7-8), 1053-1062

CODEN: ELCTDN; ISSN: 0173-0835

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal LANGUAGE: English

The polyethoxylated heterogeneous components of the so far poorly AB characterized nonionic emulsifier Cremophor EL (polyoxyl 35 castor oil) (CrEL) were fractionated by cyclodextrin-modified micellar electrokinetic capillary chromatog. (CD-MEKC). Due to the low UV absorbance of most of the CrEL-components an indirect UV detection was used with phenobarbital-sodium as background absorber. For a precise assignment of the resulting peaks to the corresponding components capillary electrophoresis (CE) had to be combined with delayed extraction-matrix assisted laser desorption/ionization-time of flight-mass spectrometry (DE-MALDI-TOF-MS) as detection system. For this purpose, the fractionating robot Probot was employed which enables both the online fractionation of the CE eluate on a MALDI target during the electrophoretic separation and the simultaneous dosage of the MALDI matrix solution The applied CrEL amount was optimized by varying the CE injection parameters time, pressure and concentration of the sample in order to obtain homolog peak series of sufficient intensity without decreasing the separation efficiency. Evaluation of the mass spectra was performed by comparing the residue masses of the homolog peak series with the calculated residue masses of potential CrEL-components. However, the high number of polyethoxylated components leads to overlapping of homolog peak series with isobaric residue masses. These isobaric interferences were detected by a high mass accuracy of the measurements (obtained by internal calibration with polyethylene glycol (PEG) 1000) and by means of the residue mass plot, the newly developed evaluation method. The combination of these techniques allowed the first detailed structure anal. of the CrEL-components showing glycerol polyoxyethylene (POE) monoricinoleate and POE monoricinoleate to be the two main components of the emulsifier. Furthermore, the coupling of CE with DE-MALDI-TOF-MS is generally applicable to the fractionation and identification of polymers.

IT 60-33-3, Linoleic acid, analysis

RL: ANT (Analyte); ANST (Analytical study)

(separation and first structure elucidation of cremophor EL-components by hyphenated capillary electrophoresis and delayed extraction-matrix assisted laser desorption/ionization-time of flight-mass spectrometry)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

 HO_2C (CH₂) 7 Z Z (CH₂) 4 Me

IT 17465-86-0, γ -Cyclodextrin

RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(separation and first structure elucidation of cremophor EL-components by
hyphenated capillary electrophoresis and delayed extraction-matrix assisted
laser desorption/ionization-time of flight-mass spectrometry)

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

REFERENCE COUNT:

35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

HCAPLUS COPYRIGHT 2007 ACS on STN L25 ANSWER 7 OF 40

ACCESSION NUMBER:

2002:368286 HCAPLUS

DOCUMENT NUMBER:

136:374550

TITLE:

A skin cream composition containing chitosan

conjugates

INVENTOR(S):

Wadstein, Jan

PATENT ASSIGNEE(S):

Wadlund AS, Norway

SOURCE:

PCT Int. Appl., 27 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

						KIND DATE			APPLICATION NO.					DATE				
	WO 2002038123								WO 2001-NO437						20011101 <			
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
							DK,											
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	
		UG,	US,	UZ,	VN,	YU,	ZA,	ZW										
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
NO	3101	76			B1		2001	0605]	NO 2	000-	5718			20	0001	113 <	
AU	2002	0164	73		A5		2002	0521	;	AU 20	002-3	1647	3		20	0011	101 <	
EP	1341	517			A1		2003	0910]	EP 20	001-	9934!	55		20	0011	101	
EP	1341	517			B1		2006	0906										
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
AT	3385	33			${f T}$		2006	0915	j	AT 2	001-	9934	55		2	0011	101	
US	2004	0439	63		A1		2004	0304	1	US 2	003-4	4166'	71		20	0309	922	
PRIORIT	Y APP	LN.	INFO	. :]	NO 2	900-!	5718		i	A 20	0001	113	

WO 2001-NO437 W 20011101

The present invention is related to compns. containing chitosan conjugated CLA (conjugated linoleic acid) and a chitosan conjugated Vitamin A or a β -cyclodextrin conjugated vitamin A. The invention also concerns the preparation of the compns. The compns. according to the invention can be used as topical and cosmetic compns. as well as pharmaceutical compns. for treatment of atypical dermatitis, psoriasis eczema as well as eczema of different origins and solar dermatitis.

RN 60-33-3 HCAPLUS


CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.


$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 7585-39-9 HCAPLUS
CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A







REFERENCE COUNT:

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

13

ACCESSION NUMBER: 2002:72541 HCAPLUS

DOCUMENT NUMBER: 136:182662

TITLE: Improved Amperometric Method for the Rapid and

Quantitative Measurement of Lipoxygenase Activity in

Vegetable Tissue Crude Homogenates

AUTHOR(S): Reyes-De-Corcuera, Jose I.; Cavalieri, Ralph P.;

Powers, Joseph R.

CORPORATE SOURCE: Department of Biological Systems Engineering,

Washington State University, Pullman, WA, 99164-6120,

USA

SOURCE: Journal of Agricultural and Food Chemistry (

2002), 50(5), 997-1001

CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

AB An improved amperometric method for rapid (2 min) quant. determination of lipoxygenase (LOX) activity in vegetable tissue crude homogenates is presented. Measured LOX activity was linear (R2 > 0.99) throughout the entire activity range for green bean and for corn below 70% activity. The resolution was 0.4% or 1.11 μmol L-1 s-1 of oxygen. The limit of detection was 3.43 μmol L-1 s-1 of oxygen. The amperometric method was improved by encapsulating linoleic acid (LA) in β -cyclodextrin (CD) resulting in a stable substrate-buffer solution at a pH below 8.0. Ethanol and Tween 20 were not effective in solubilizing high LA concns. required by the assay. A prototype benchtop instrument with the potential for use in an industrial environment is also presented.

IT 60-33-3, Linoleic acid, uses 7585-39-9,


β-Cyclodextrin

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (lipoxygenase activity in vegetable tissue crude homogenates determined by amperometry with encapsulating linoleic acid in β -cyclodextrin)

RN 60-33-3 HCAPLUS


CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)



PAGE 2-A

REFERENCE COUNT:

17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 9 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:584837 HCAPLUS

DOCUMENT NUMBER: 136:221495

TITLE: The effect of a new skin ointment on skin thickness

OH

and elasticity

AUTHOR(S): Thom, E.; Gudmundsen, O.; Wadstein, J.

CORPORATE SOURCE: Parexel Norway AS, Lillestrom, Norway SOURCE: Journal of Applied Cosmetology (2001),

19(2), 51-57

CODEN: JACOEL; ISSN: 0392-8543

PUBLISHER: International Ediemme

DOCUMENT TYPE: Journal LANGUAGE: English

AB The present open pilot study was carried out in order to investigate a new patented concept for skin treatment. The new concept is intended for use in treatment of ageing skin. The ointment contains conjugated linoleic acid (CLA) and retinyl palmitate (RP). Both ingredients are conjugated with the biopolymer chitosan in order to improve water solubility, increase skin penetration and inhibit oxidation of the active substances. A number of studies have previously been carried out with conjugated retinyl palmitate, where the conjugation mostly has been done using β-cyclodextrin. We included 20 females in our study and the treatment period was three months. Objective measurements of

skin-thickness and elasticity were carried out initially and after three months. Subjective observations and scores were performed by the participants themselves using visual analog scales (VASs) initially and at the end of the study. The results showed a significant improvement in skin quality both with regard to objective as well as in subjective parameters after treatment with the new ointment. In comparison to our previous studies with ointments containing only conjugated RP the effects on skin thickness and elasticity were more pronounced with the new formulation showing an average improvement in skin thickness of 51% and in skin elasticity of 27%. The self evaluation scores of the participants were also highly favorable and significant, and all of the participants would like to continue with the ointment after the formal study was closed. The tolerability of the treatment was excellent and all subjects concluded the study according to the protocol.

IT 7585-39-9, β -Cyclodextrin.


RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (effect of new skin ointment on skin thickness and elasticity)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Н

PAGE 2-A

IT 60-33-3DP, Linoleic acid, conjugates with chitosan RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (effect of new skin ointment on skin thickness and elasticity)

Roy P. Issac

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

REFERENCE COUNT:

7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:223475 HCAPLUS

DOCUMENT NUMBER: 135:32774

TITLE: Optimisation of nutritional requirements and process

control parameters for the production of HA-2-91, a

new tetraene polyene antibiotic

AUTHOR(S): Gupte, T. E.; Naik, S. R.

CORPORATE SOURCE: Laboratory of Industrial Microbiology and

Fermentation, Research and Development Centre, Hindustan Antibiotics Ltd., Pune, 411 018, India

SOURCE: Hindustan Antibiotics Bulletin (1998),

40(1-4), 5-13

CODEN: HINAAU; ISSN: 0018-1935

PUBLISHER: Hindustan Antibiotics, Ltd

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:32774

HA-2-91, a new tetraene polyene antibiotic produced during submerged fermentation of Streptomyces arenae var ukrainiana. Optimization of nutritional requirements and process control parameters were studied for higher productivity of HA-2-91 during fermentative production in shaken flasks using complex media. Exptl. findings indicate that jowar starch (Sorghum vulgare) is the best carbon source while corn steep liquor in combination with peanut meal are the best nitrogen sources. Exogenous addition of amino acids, divalent cations and fatty acids suppressed the productivity of HA-2-91. Incorporation of glucose into the production medium above 5% (w/v) results in inhibition of productivity of HA-2-91 which may be due to catabolite regulation. The concentration of phosphate ions above 10 ppm also showed similar suppression effect on the productivity of HA-2-91. However, ferrous ions at 100 ppm showed slight stimulatory effect on the production of HA-2-91. The optimum process control parameters for the production of HA-2-91 were found to be temperature, 28°C; inoculum concentration from seed to production medium, 1% (volume/volume); pH and volume of production medium 6.5 and 100 mL resp.; and fermentation cycle time, 120 h.

IT 60-33-3, Linoleic acid, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process);
BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(optimization of nutritional requirements and process control parameters for the production of HA-2-91, a new tetraene polyene antibiotic)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 $(CH_2)_7$ Z Z $(CH_2)_4$ Me

IT 7585-39-9, β -Dextrin

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(optimization of nutritional requirements and process control parameters for the production of HA-2-91, a new tetraene polyene antibiotic)


RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:136991 HCAPLUS

DOCUMENT NUMBER: 134:198075

TITLE: Triglyceride-free compositions and methods for

enhanced absorption of hydrophilic therapeutic agents

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

```
PATENT NO.
                                           APPLICATION NO.
                        KIND
                               DATE
                                                                  DATE
                                           WO 2000-US18807
    WO 2001012155
                         A1
                               20010222
                                                                  20000710 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
            ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                               20011030
                                           US 1999-375636
     US 6309663
                         B1
                                                                 19990817 <--
                                                                20000710 <--
    CA 2380642
                         A1
                               20010222
                                           CA 2000-2380642
                    A1
                               20020605
                                           EP 2000-947184
     EP 1210063
                                                                  20000710 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
                                           JP 2001-516502
    JP 2003506476
                         \mathbf{T}
                               20030218
                                                                  20000710
    NZ 517659
                         A
                               20041224
                                           NZ 2000-517659
                                                                  20000710
                         B2 20050421 AU 2000-60838
    AU 780877
                                                                  20000710
    US 2001024658
                         A1
                                           US 2000-751968
                                                                  20001229 <--
                               20010927
    US 6458383
                         B2
                               20021001
PRIORITY APPLN. INFO.:
                                           US 1999-375636
                                                               A 19990817
                                           WO 2000-US18807
                                                               W 20000710
```

The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT 60-33-3, Linoleic acid, biological studies 7585-39-9D,

β-Cyclodextrin, ethers with propanediol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me


RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

1

2000:56548 HCAPLUS ACCESSION NUMBER:

132:194033 DOCUMENT NUMBER:

Kinetic study of the oxidation of linoleic acid by TITLE:

lipoxygenase in presence of β -cyclodextrin

Lopez-Nicolas, J. M.; Bru, R.; Lopez-Roca, J. M.; AUTHOR(S):

Garcia-Carmona, F.

E.T.S. Ingenieros Agronomos. Department of Food CORPORATE SOURCE:

Technology, University of Murcia, Spain

Proceedings of the International Symposium on SOURCE: Cyclodextrins, 9th, Santiago de Comostela, Spain, May

31-June 3, 1998 (1999), Meeting Date 1998,

525-528. Editor(s): Labandeira, J. J. Torres; Vila-Jato, J. L. Kluwer Academic Publishers:

Dordrecht, Neth. CODEN: 68NHAE

DOCUMENT TYPE: Conference English LANGUAGE:

The oxidation of linoleic acid entrapped in β -CD by lipoxygenase was AB characterized and a model for enzyme catalysis in a CD medium is proposed.

7585-39-9, β-Cyclodextrin IT

RL: CAT (Catalyst use); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or

reagent); USES (Uses)


(inhibitor; kinetic study of oxidation of linoleic acid by lipoxygenase in presence of β -cyclodextrin)

RN 7585-39-9 HCAPLUS


CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




IT 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(kinetic study of oxidation of linoleic acid by lipoxygenase in presence of β -cyclodextrin)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:790366 HCAPLUS

DOCUMENT NUMBER: 128:93107

TITLE: Percutaneous absorption and histopathology of a

poloxamer-based formulation of capsaicin analog

AUTHOR(S): Lee, Beom-Jin; Lee, Tae-Sup; Cha, Bong-Jin; Kim,

Soon-Hoe; Kim, Won-Bae

CORPORATE SOURCE: College of Pharmacy, Biological Rhythm and Controlled

Release Laboratory, Kangwon National University,

Chuncheon, 200-701, S. Korea

SOURCE: International Journal of Pharmaceutics (1997)

), 159(1), 105-114

CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

A new synthetic capsaicin analog (CA) modified with 4-hydroxyl and alkyl AB chain of capsaicin was synthesized as a potent anti-inflammatory analgesic drug and is now on clin. trial in Korea. The purpose of this study was to investigate the percutaneous absorption and histopathol. of a poloxamer-based formulation of CA. A poloxamer-based gel was prepared by cold method using poloxamer 407. Vertical Franz type diffusion cells were used for skin penetration of drug against receptor phase filled with about 10 mL of 0.9 isotonic saline at 32°C. The concentration of drug was determined by the reverse phased HPLC (C18, Symmetry®) with fluorometeric detector. Total amount of CA free base permeated was higher than that of the CA salt form. Percutaneous absorption of CA was greatly enhanced in ethanol and PG than that in water, 2-hydroxypropy-β-cyclodextrin and PEG400. As ethanol concentration increased, percutaneous absorption greatly increased. The flux rate of CA increased slightly when PG was added to ethanol solution The marked enhancing effect of the 5 fatty acid IPM in cosolvents was also noted on the percutaneous absorption of a poloxamer-based formulation of CA. Addition of 5 OA and 5 LA into the gel containing 5 IPM resulted in a slight increase in skin permeation. No significant difference in skin permeation was observed as a function of poloxamer content (20, 25 and 30). The buffer system of 30 poloxamer-based gel slightly changed the cumulative amts. of CA penetrated for 24 h. The flux of poloxamer-based gels increased linearly as the drug concentration increased. There was a variation of percutaneous absorption of the drug, depending on the species used. The flux of a poloxamer-based formulation of CA was the highest in case of hairless mice but the lowest in hamsters. No skin erythema and histopathol. changes were observed on the dorsal site of hairless mice in six groups after a week or two months application, suggesting no skin toxicity of the poloxamer-based gel. Based on these findings, the current poloxamer-based formulation appears useful in the systemic delivery of CA as topical or transdermal patch formulations.

IT 60-33-3, Linoleic acid, biological studies 7585-39-9D, β-Cyclodextrin, 2-hydroxypropyl ether

RL: BPR (Biological process); BSU (Biological study, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological

study); PROC (Process); USES (Uses)
(percutaneous absorption and histopathol. of a poloxamer-based formulation of capsaicin analog)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

 HO_2C (CH₂) 7 Z Z (CH₂) 4 Me


Roy P. Issac

7585-39-9 HCAPLUS RN


β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS 21 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1997:681639 HCAPLUS

DOCUMENT NUMBER:

127:358219

TITLE:

Oxidative stability and nuclear magnetic resonance

analyses of linoleic acid encapsulated in

cyclodextrins

AUTHOR(S):

Reichenbach, Wendy A.; Min, David B.

CORPORATE SOURCE:

Department of Food Science, The Ohio State University,

Columbus, OH, 43210, USA

SOURCE:

Journal of the American Oil Chemists' Society (

1997), 74(10), 1329-1333

CODEN: JAOCA7; ISSN: 0003-021X

PUBLISHER:

AOCS Press

DOCUMENT TYPE:

Journal

LANGUAGE:

English

The effects of α - and β -cyclodextrin (CD) on the oxidative AB stability of linoleic acid (LA) at 35°C were studied by measuring headspace oxygen depletion in airtight 35-mL serum bottles. LA was encapsulated in $\alpha\text{-CD}$ or $\beta\text{-CD}$ in an aqueous solution during homogenization at 8000 rpm for 1 min and then dried under vacuum for 60 h at room temperature Headspace oxygen was measured by thermal conductivity gas chromatog. The rate of oxygen depletion for the control, which contained LA only, was 93.8 μ mole/L·h. The rates of oxygen depletion for LA, encapsulated at a 1:1 mol ratio (mole CD/mol LA) in α -CD and $\beta\text{-CD},$ were 13.8 and 111 $\mu\text{moles/L}\cdot\text{h},$ resp. When LA was encapsulated in $\alpha\text{-CD}$ and $\beta\text{-CD}$ at a 2:1 mol ratio (moles CD/mol LA), the rates of oxygen depletion were 0.573 and 53.9 μ moles/L·h, resp. Although α -CD protected LA from reaction with oxygen at both ratios, the rate of oxygen depletion by LA encapsulated in β -CD at a 1:1 mol ratio was not statistically different from the control. β -CD protected LA from reaction with oxygen at a 2:1 mol ratio. 1H NMR spectra of the complexes formed from 1:1 mol ratios of LA and CD indicated that LA was encapsulated in α -CD or β -CD.

O-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(oxidative stability and NMR analyses of linoleic acid encapsulated in

(oxidative stability and NMR analyses of linoleic acid encapsulated in cyclodextrins)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

IT 7585-39-9, β-Cyclodextrin 10016-20-3,

α-Cyclodextrin

RL: PEP (Physical, engineering or chemical process); PROC (Process) (oxidative stability and NMR analyses of linoleic acid encapsulated in cyclodextrins)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:547073 HCAPLUS

DOCUMENT NUMBER: 127:132573

TITLE: Potato (Solanum tuberosum var. Desiree) tuber

5-lipoxygenase selectivity for the physicochemical

properties of linoleic acid

AUTHOR(S): Bru, Roque; Garcia-Carmona, Francisco

CORPORATE SOURCE: Departamento de Bioquimica y Biologia Molecular A.

Facultad de Biologia, Universidad de Murcia, Murcia,

E-30001, Spain

SOURCE: Journal of Agricultural and Food Chemistry (

1997), 45(8), 2869-2875

CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

The dependence of potato 5-lipoxygenase (LOX) activity on the physicochem. AB properties of linoleic acid (LA) was studied. β -Cyclodextrin (β-CD) and pH were used as tools to investigate the effect of the physicochem. state of LA on LOX kinetic properties in vitro. The LA concentration dependence of LOX activity was best fitted by using the Hill equation. It was found that the decrease in LOX activity at high pH corresponded to a pKa lower than the pKa of LA; thus, such decrease was assigned to some ionizable side-chain group of LOX related to the active center. At a fixed LA concentration, the presence of β -CD led to a decrease in the LOX reaction rate, which was due to its effect on Km and the Hill constant since Vmax was not affected. Expts. in the presence of β -CD revealed that LA monomers were also used as substrate, although less efficiently than aggregates. The different activities exhibited against monomers and aggregates is the reason for the observed apparent substrate cooperativity, which can be interpreted as an aggregate-induced enzyme activation. The effect of β -CD on LOX activity could be explained on the basis of the specific interaction between LA and β -CD and the equations derived for such interaction developed in a previous work.

IT 7585-39-9, β-Cyclodextrin

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(dependence of potato tuber 5-lipoxygenase on physicochem. properties of linoleic acid: effect of β -cyclodextrin)

RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



IT 60-33-3, Linoleic acid, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(dependence of potato tuber 5-lipoxygenase on physicochem. properties of linoleic acid: effect of β -cyclodextrin)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

REFERENCE COUNT:

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:275188 HCAPLUS

DOCUMENT NUMBER: 126:342682

TITLE: Composition and functional properties of cholesterol

reduced egg yolk

AUTHOR(S): Awad, A. C.; Bennink, M. R.; Smith, D. M.

CORPORATE SOURCE: Department of Food Science and Human Nutrition,

Michigan State University, East Lansing, MI,

PUBLISHER:

48824-1224, USA

SOURCE: Poultry Science (1997), 76(4), 649-653

CODEN: POSCAL; ISSN: 0032-5791
Poultry Science Association, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

The composition and functional properties of cholesterol reduced egg yolk AB (CREY) were compared to those of control egg yolk (EY). The CREY was prepared by absorbing cholesterol with β -cyclodextrin after dilution and dissociation of granules at pH 10.5. The CREY contained less lipid and protein and more carbohydrate and ash than EY. Egg lipids were fractionated into triglycerides, cholesterol esters, free cholesterol, phosphatidyl choline, and phosphatidyl ethanolamine. Free and esterified cholesterol in CREY were reduced by 91.6 and 94.4%, resp. Triglycerides were the major lipid class in CREY. The CREY contained more oleic acid and less linoleic acid than the control. Protein solubility in 0.1 and 0.6 M NaCl and sponge cake volume did not differ. The composition of proteins soluble in 0.6 M NaCl in both egg prepns. were similar as determined by SDS-polyacrylamide gel electrophoresis. The electrophoretic profiles of proteins soluble in 0.1 M NaCl were similar, except that lipovitellin from EY was insol. under these conditions. The CREY was less yellow than EY, as indicated by β -carotene concns. and Hunter b values. Thus, β -cyclodextrin can be used to produce a low cholesterol egg product with compositional and functional properties similar to EY.

IT 60-33-3, Linoleic acid, biological studies

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(composition and functional properties of cholesterol reduced egg yolk)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

IT 7585-39-9, β -Cyclodextrin


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(composition and functional properties of cholesterol reduced egg yolk)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A

L25 ANSWER 17 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1997:259764 HCAPLUS

DOCUMENT NUMBER:

126:242891

TITLE:

Mucosal preparation containing physiologically active

peptide

INVENTOR(S):

Yamamoto, Nakayuki; Ito, Teruomi

PATENT ASSIGNEE(S):

Asahi, Kasei Kogyo Kabushiki Kaisha, Japan; Hisamitsu

Seiyaku Kabushiki Kaisha; Yamamoto, Nakayuki; Ito,

Teruomi

SOURCE:

PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

1

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
	A1 19970227	WO 1996-JP2277	19960812 <			
W: CA, CN, JP,			MC NI DE CE			
		R, GB, GR, IE, IT, LU,				
JP 11292787	A 19991026	JP 1995-208010	19950815 <			
CN 1179723	A 19980422	CN 1996-192821	19960812 <			
EP 845265	A1 19980603	EP 1996-926626	19960812 <			
R: AT, BE, CH,	DE, DK, ES, FR, G	B, GR, IT, LI, LU, NL,	SE, MC, PT,			

IE, FI

JP 3824023 B2 20060920 JP 1997-509140 19960812 PRIORITY APPLN. INFO.: JP 1995-208010 A 19950815 WO 1996-JP2277 W 19960812

OTHER SOURCE(S): MARPAT 126:242891

AB This invention related to a mucosal preparation obtained by blending a physiol. active peptide at least with a sorbefacient and a vasodilatory compound Owing to the combined use of the sorbefacient with the vasodilatory compound, the absorption of any desired physiol. active peptide can be enhanced and thus it can be self-administered to a patient without giving any pain caused by parenteral injection. Therefore, it is highly useful as a preparation of a physiol. active peptide for prolonged administration. As the physiol. active peptide, use can be made of insulin, calcitonin, human PTH, somatostatin, glucagon, etc. As the sorbefacient, use can be made of bile acid salts, cyclodextrin, phospholipids, nonionic surfactants, higher fatty acids, etc. As the vasodilatory compds., use can be made of calcium channel inhibitors, prostaglandin E1, isosorbide nitrate, nitroglycerin, etc.

IT 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies 7585-39-9, β -Cyclodextrin 10016-20-3,

 α -Cyclodextrin 17465-86-0, γ -Cyclodextrin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sorbefacient and vasodilatory compound in mucosal preparation containing physiol. active peptide)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

HO-CH2

L25 ANSWER 18 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:228761 HCAPLUS

DOCUMENT NUMBER: 126:313923

TITLE: Cyclodextrins as hosts for poorly water-soluble

compounds in enzyme catalysis

AUTHOR(S): Bru, Roque; Lopez-Nicolas, Jose M.; Nunez-Delicado,

Estrella; Nortes-Ruiperez, Dolores; Sanchez-Ferrer,

Alvaro; Garcia-Carmona, Francisco

CORPORATE SOURCE: Departamento de Bioquimica y Biologia Molecular A,

Facultad de Biologia, Universidad de Murcia, Murcia,

E-30001, Spain

SOURCE: Applied Biochemistry and Biotechnology (1997

), Volume Date 1996, 61(1/2, Biocatalysis-95), 189-198

CODEN: ABIBDL; ISSN: 0273-2289

PUBLISHER: Humana
DOCUMENT TYPE: Journal
LANGUAGE: English

The capability of cyclodextrins to enhance greatly the solubility in water of poorly water-soluble substances makes them an ideal alternative for investigating the expression of enzyme activity with such substrates in aqueous solution. This capability is demonstrated by using soybean lipoxygenase with linoleic acid/ β -cyclodextrin and diethylstilbestrol/ γ -

cyclodextrin, and cholesterol oxidase with cholesterol/methyl- β -

cyclodextrin.

IT 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(lipoxygenase substrate, solubilized with β -cyclodextrin; use in

enzyme catalysis of cyclodextrin-mediated solubility enhancement of poorly water-soluble substrate compds.)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

TT 7585-39-9, β-Cyclodextrin 7585-39-9D,
β-Cyclodextrin, Me ethers 17465-86-0, γ-Cyclodextrin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
 (use in enzyme catalysis of cyclodextrin-mediated solubility enhancement of

(use in enzyme catalysis of cyclodextrin-mediated solubility enhancement of poorly water-soluble substrate compds.)

RN 7585-39-9 HCAPLUS


CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 2-A

RN 7585-39-9 HCAPLUS
CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)



PAGE 2-A

RN 17465-86-0 HCAPLUS CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

L25 ANSWER 19 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1996:572123 HCAPLUS

125:219760 DOCUMENT NUMBER:

TITLE:

A method of producing a taxane-type diterpene Yukimune, Yukihito; Hara, Yasuhiro; Tan, Hiroaki;

Tomino, Ikuo

PATENT ASSIGNEE(S):

Mitsui Petrochemical Industries, Ltd., Japan

SOURCE:

Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	DATE		
EP 727492	A2	19960821	EP 1995-308498	19951127·	<		
EP 727492	A3	19961016					
EP 727492	B1	20010131		•			
R: DE, FR, GB,	IT, NL						
JP 08140690	A	19960604	JP 1994-291783	19941125	<		
JP 3549594	B2	20040804					
JP 08163991	A	19960625	JP 1994-312258	19941215	<		
JP 09065889	A	19970311	JP 1995-218874	19950828	<		
JP 3625908	B2	20050302	•				
JP 08205882	A	19960813	JP 1995-301654	19951120	<		
JP 3746550	B2	20060215					
PRIORITY APPLN. INFO.:			JP 1994-291783	A 19941125	•		
			JP 1994-301179	A 19941205			
•			JP 1994-312258	A 19941215			
			JP 1995-218874	A 19950828			

OTHER SOURCE(S): MARPAT 125:219760

A simple method of producing a taxane-type diterpene by plant tissue AB culture is disclosed. Productivity can be improved by carrying out the culture in the presence of coronatines, a bacterium that produced the coronatines, a culture solution or a culture extract of such bacteria, cyclic polysaccharides, fatty acids, or an amino or imino derivative of jasmonic acids.

60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies IT 7585-39-9, β-Cyclodextrin 10016-20-3,

 α -Cyclodextrin 17465-86-0, γ -Cyclodextrin

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(producing taxane-type diterpenes by Taxus tissue culture)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME) CN


Double bond geometry as shown.

$$(CH_2)$$
 7 Z Z (CH_2) 4 Me

RN7585-39-9 HCAPLUS

β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

PAGE 2-A



RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

$$HO-CH_2$$
 OH
 OH

L25 ANSWER 20 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:529405 HCAPLUS

DOCUMENT NUMBER: 125:188986

TITLE: Cyclodextrins as molecular tools to investigate the

surface properties of potato 5-lipoxygenase

AUTHOR(S): Bru, R.; Lopez-Nicolas, J. M.; Sanchez-Ferrer, A.;

Garcia-Carmona, F.

CORPORATE SOURCE: Facultad Biologia, Universidad Murcia, Murcia,

E-30080, Spain

SOURCE: Progress in Colloid & Polymer Science (1996

), 100 (Trends in Colloid and Interface Science X),

276-280

CODEN: PCPSD7; ISSN: 0340-255X

PUBLISHER: Steinkopff
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The behavior of potato 5-lipoxygenase acting on both monomeric and aggregated linoleic acid has been studied. While the substrate preparation was transparent, lipoxygenase activity was determined by means of a spectrophotometric method, which was not useful to determine the activity in turbid samples. In the latter case a polarog, method was used. Cyclodextrins were used to increase the range of monomeric, and thus transparent, linoleic acid. This clearly revealed that potato 5-lipoxygenase can be saturated by linoleic acid monomers but when aggregates are formed at higher linoleic acid concentration, activity raises and stabilizes in a new saturation level.>. This was interpreted as an activation of lipoxygenase induced by the aggregation of its substrate, linoleic acid. Kinetic parameters were determined in each region - monomeric and aggregate - and are consistent with the surface activation hypothesis.

IT 60-33-3, Linoleic acid, biological studies 7585-39-9,

β-Cyclodextrin

RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(cyclodextrins as mol. tools to investigate the surface properties of

potato 5-lipoxygenase)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.


$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me


RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 2-A

L25 ANSWER 21 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:364944 HCAPLUS

DOCUMENT NUMBER: 125:56734

TITLE: Influence of maltodextrin, cyclodextrin and palm oil

on the aroma retention of apricot powders

AUTHOR(S): Di Cesare, L. F.; Nani, R.; Mariani, N.; D'Angelo, V.

CORPORATE SOURCE: Instituto Sperimentale Ia Valorizzazione Tecnologica

Prodotti Agricoli, Milan, 20133, Italy

SOURCE: Industrie delle Bevande (1996), 25(142),

Roy P. Issac

101-107

CODEN: INBEEW; ISSN: 0390-0541

PUBLISHER: Chiriotti
DOCUMENT TYPE: Journal
LANGUAGE: Italian

The volatile compds. retention of the apricot powders, prepared by a vacuum AB static and a vacuum belt dryer, was studied. The apricot pulp, after partial enzymic pectinolysis, was separated by a decanter and then the juice was concentrated at 54°Brix. The natural volatile compds. (natural extract) were recovered from the distillate by KS112 resin. The juice concentrate, before being dried, was aromatized with natural-identical compds. (model mixture) or natural volatile compds. incorporated into maltodextrin, palm oil, or encapsulated into β -cyclodextrin. The determination of volatile compound retention in the powders was carried out by GC/MS-SIM quant. anal. The preliminary results obtained with a static dryer pointed out that the retention of natural-identical compds. in the apricot powders increased in the presence of maltodextrin, β -cyclodextrin, maltodextrin + β -cyclodextrin and palm oil + maltodextrin, while not in the powders without these substances. The juice concentrate containing both model mixture and natural volatile extract had the same results, when they were incorporated or encapsulated into the same substances and submitted to the vacuum belt dryer. There was also a sensorial test for color, odor, aroma, and taste. The powders aromatized with natural compds. and prepared by a vacuum belt dryer were reconstituted at 10°-11°Brix with H2O dist. The juices were then compared with a test juice obtained from the reconstitution at 10°-11°Brix of the juice concentrate (54°Brix), and aromatized with natural volatile extract For the aroma, odor, and taste, all the samples were acceptable. On the contrary, the juices containing maltodextrin and maltodextrin $+ \beta$ -cyclodextrin were less colored than the test juice.


IT 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)

(maltodextrin, cyclodextrin, and palm oil effect on the aroma and volatile compound retention of apricot powders)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 7585-39-9, β -Cyclodextrin

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses) (maltodextrin, cyclodextrin, and palm oil effect on the aroma retention of apricot powders)


RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L25 ANSWER 22 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:753643 HCAPLUS

DOCUMENT NUMBER:

123:152922

TITLE:

Transparent liquid for encapsulated drug delivery

INVENTOR(S):

Yiv, Seang H. Ibah, Inc., USA

PATENT ASSIGNEE(S):

PCT Int. Appl., 66 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.			KIN	IND DATE		APPLICATION NO.						DATE					
WO 9514037			A1 19950526			1	WO 1994-US13394				19941116 <						
	W:	AM,	AT,	AU,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CZ,	DE,	DK,	EE,	ES,	FI,
		GB,	GE,	HU,	JP,	KE,	KG,	KP,	KR,	KZ,	LK,	LR,	LT,	LU,	LV,	MD,	MG,
		MN,	MW,	NL,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SI,	SK,	TJ,	TT,	UA,
		US,	UZ														
	RW:	KE,	MW,	SD,	SZ,	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IE,	IT,	LU,
		MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,	MR,	NE,	SN,
		TD,	TG														
CA	2176	927			A 1	A1 19950526			CA 1994-2176927						19941116 <		
AU 9512917			Α		19950606 AU 1995-12917 19941:						116 <						

```
B2
                               19980611
    AU 692506
                                                                 19941116 <--
    EP 736041
                         A1
                               19961009
                                          EP 1995-904099
    EP 736041
                         B1
                               20060208
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
                               19971014
                                          JP 1994-514649
                                                                 19941116 <--
    JP 09510182
                         T
                              20060215 AT 1995-904099
    AT 317397
                         {f T}
                                                                19941116
    US 5707648
                               19980113
                                          US 1995-406935
                                                                19950517 <--
                                          US 1993-153846
                                                              A 19931117
PRIORITY APPLN. INFO.:
                                          WO 1994-US13394
                                                              W 19941116
```

AB A stable transparent multi-component composition useful for the delivery of water soluble active agents to animals is provided. The compns. are formulated with a mixture of an oil phase, an aqueous phase, and a surfactant system, along with the active agent to be delivered to the animal. The compns. are specially formulated to be compatible with capsules such as gelatin and starch capsules. The aqueous phase of the compns. contains a substantial amount of polyethylene glycol and can optionally also contain a plasticizer. Preferred active agents are proteinaceous materials. Calcein bioavailability from a transparent liquid containing Captex 200 12, Imwitor 308 29.8, Tween 80 19.2, PEG 400 32.4, sorbitol 1.6, water 3% weight/weight, and 100 mM calcein solution in 10 mM Tris pH 7.4 3% weight/weight, resp., was studied.

IT 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies 7585-39-9, β Cyclodextrin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transparent liquid compns. for encapsulated drug delivery)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me


RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L25 ANSWER 23 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:628687 HCAPLUS

DOCUMENT NUMBER: 123:50376

TITLE: Aggregation of polyunsaturated fatty acids in the

presence of cyclodextrins

AUTHOR(S): Bru, Roque; Lopez-Nicolas, Jose M.; Garcia-Carmona,

Francisco

CORPORATE SOURCE: Dep. Bioquim. Biol. Mol. "A", Univ. Murcia, Murcia,

E-30001, Spain

SOURCE: Colloids and Surfaces, A: Physicochemical and

Engineering Aspects (1995), 97(3), 263-9

CODEN: CPEAEH; ISSN: 0927-7757

PUBLISHER: Elsevier DOCUMENT TYPE: Journal LANGUAGE: English

The aggregation behavior of the polyunsatd. fatty acids (PUFA) linoleic acid and arachidonic acid was studied in the presence of cyclodextrins (CDs). The influence of CD concentration on CMC of PUFA suggests that two CD mols. bind sequentially to one mol. of PUFA. Two equilibrium consts., K1 representing the interaction of the first CD mol., and K2, the interaction of the second, were determined by non-linear regression of the PUFA CMC vs. CD concentration data to an expression deduced from the reaction scheme in the equilibrium. The effect of pH and the structure of the CD on the equilibrium consts. was studied. It is postulated that the first CD mol. interacts with the carboxyl group of PUFA through hydrogen bonding when the fatty acid is

protonated, while the second CD mol. binds to the hydrocarbon chain of the PUFA through hydrophobic interaction. The formation of hydrogen bonds was principally affected by the inner diameter of the CD, while the hydrophobic interactions were very strongly affected by the polarity of the CD group coating the inner channel. The relevance of the results for the development of enzyme assays involving fatty acids is discussed.

IT 60-33-3, Linoleic acid, properties 7585-39-9, β Cyclodextrin 7585-39-9D, β Cyclodextrin, ethers with methanol 10016-20-3, α Cyclodextrin 17465-86-0, γ Cyclodextrin

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)

(aggregation of polyunsatd. fatty acids in presence of cyclodextrins)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z (CH₂) 4 Me

RN 7585-39-9 HCAPLUS
CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

OH OH OH HO. R R S OH OH OH HO-R OH ОH HO OH OH HO HO-НО OH H


PAGE 2-A

PAGE 1-A

RN 7585-39-9 HCAPLUS CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Н

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

L25 ANSWER 24 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:485889 HCAPLUS

DOCUMENT NUMBER:

122:263834

TITLE:

Entrapment of liquid lipids into powdery matrixes of

saccharides and proteins

AUTHOR(S):

Matsuno, Ryuichi; Imagi, Jun; Adachi, Shuji Fac. Agric., Kyoto Univ., Kyoto, 606-01, Japan

CORPORATE SOURCE: SOURCE:

Dev. Food Eng., Proc. Int. Congr. Eng. Food, 6th (

1994), Meeting Date 1993, Volume Pt. 2,

1065-7. Editor(s): Yano, Toshimasa; Matsuno, Ruuichi;

Nakamura, Kozo. Blackie: Glasgow, UK.

CODEN: 61FFAL

DOCUMENT TYPE: Conference LANGUAGE: English

The emulsifying activity, the high stabilizing activity of the emulsion and the formation of a fine dense skin layer during drying were the properties of agents that effectively entrapped liquid lipids. Gum arabic and gelatin were effective. Addition of an agent having a property to a base agent lacking the property improved the entrapment. Oxidation of entrapped liquid lipid was retarded. However, the extent of retardation depended on the kind of lipids and the kind of entrapping agents. Oxidation processes of some combinations of lipids and entrapping agents were expressed by a kinetic model including oxygen diffusion through dehydrated entrapping agents. Et eicosapentaenoate was also stabilized by the entrapment.

IT 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, processes

10016-20-3, α -Cyclodextrin

RL: PEP (Physical, engineering or chemical process); PROC (Process) (entrapment of liquid lipids into powdery matrixes of saccharides and proteins)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 25 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:13452 HCAPLUS

DOCUMENT NUMBER: 122:4734

TITLE: Solubilization of fatty acids and similar lipids by

methylated cyclodextrins

AUTHOR(S): Szente, L.; Szejtli, J.; Kato, L.

CORPORATE SOURCE:

CYCLOLAB, Cyclodextrin Res. and Dev. Lab. Ltd.,

Budapest, 1026, Hung.

SOURCE:

Minutes Int. Symp. Cyclodextrins, 6th (1992)

, 340-4. Editor(s): Hedges, Allan R. Ed. Sante:

Paris, Fr. CODEN: 60BCAL

DOCUMENT TYPE:

Conference English

LANGUAGE:

AB

Naturally occurring lipids were transformed into water soluble forms by using chemical modified cyclodextrins as solubilizers. DIMEB (2,6-dimethyl- β CD), randomly methylated β CD(RAMEB) and HPBCD (2-bydroxypropyl-BCD) were compared as solubility enhancers. DIMEB and RAMEB

(2-hydroxypropyl-BCD) were compared as solubility enhancers. DIMEB and RAMEB were the most potent solubilizers for fatty acids and other studied natural lipophiles. Solid complexes were prepared via freeze-drying with an average lipid content of 2 to 5%. By dissolving these formulations clear, stable aqueous solns. are obtained. The real mol. dispersity of the fatty acids in this form was probably responsible for the very promising results obtained in the first successful in vitro cultivation of leprosy bacilli using soluble palmitic acid complexes. This findings may open a new way in the chemotherapy of leprosy.

IT 7585-39-9D, β -Cyclodextrin, alkyl ethers

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); NUU (Other use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)


(solubilization of fatty acids and similar lipids by methylated cyclodextrins)

RN 7585-39-9 HCAPLUS


CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 60-33-3, Linoleic acid, biological studies

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL


(Biological study)

(solubilization of fatty acids and similar lipids by methylated cyclodextrins)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 26 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:491478 HCAPLUS

DOCUMENT NUMBER: 121:91478

TITLE: Release control of isosorbide dinitrate by

cyclodextrin complexation

AUTHOR(S): Seo, H.; Oh, K.; Hirayama, F.; Uekama, K.

CORPORATE SOURCE: Dep. Pharm., Miyazaki Med. Coll. Hosp., Kiyotake,

889-16, Japan

SOURCE: Minutes Int. Symp. Cyclodextrins, 6th (1992)

, 543-6. Editor(s): Hedges, Allan R. Ed. Sante:

Paris, Fr.
CODEN: 60BCAL
Conference

DOCUMENT TYPE: Conference English

The permeation of isosorbide dinitrate (ISDN) through the skin of hairless mice was significantly enhanced when the drug was administered as suspension containing 2-hydroxypropyl- β -cyclodextrin (HP- β -CyD). The skin permeation of ISDN was much more enhanced after the co-administration of HP- β -CyD and unsatd. fatty acids employed. On the other hand, the permeation of ISDN was decreased when the drug was administered as solution with HP- β -CyD.

IT 7585-39-9D, β -Cyclodextrin, ethers with propanediol


RL: BIOL (Biological study)

(isosorbide dinitrate skin permeation control by complexation with)


RN 7585-39-9 HCAPLUS

CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 60-33-3, Linoleic acid, biological studies


RL: BIOL (Biological study)

(isosorbide dinitrate skin permeation control by complexation with hydroxypropyl β -cyclodextrin and)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 27 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:579303 HCAPLUS

DOCUMENT NUMBER:

119:179303

TITLE:

Utilization of cyclodextrin as fat soluble compound

carrier to serum-free culture of rat astrocytes

Nakama, Akihiko

CORPORATE SOURCE:

Osaka City Inst. Public Health Environ. Sci., Osaka,

543, Japan

SOURCE:

AUTHOR(S):

Annual Report of Osaka City Institute of Public Health

and Environmental Sciences (1992), Volume

Date 1991, 54, 48-53

CODEN: AOISDR; ISSN: 0285-5801

DOCUMENT TYPE: Journal LANGUAGE: Japanese

acids were prepared and examined as replacements for bovine serum albumin as fat-soluble compound carriers on cultured rat astrocytes. In serum-supplemented medium, it was difficult to evaluate the effects of fat-soluble compds. in serum on cell growth. Therefore, serum-free chemical defined medium supplemented with growth factors, hormones, and nutrients was developed for rat astrocytes to evaluate these effects. $\alpha\text{-Cyclodextrin}$ complexes with 3 vitamins (vitamin A acetate, E, and K1) and 3 fatty acids (linoleic, linolenic, and oleic acids) showed growth promoting activities for astrocytes in serum-free medium. Usually, supplementing fat-soluble compds. to a cell culture medium is very difficult, especially to a low or no protein medium, but $\alpha\text{-cyclodextrin}$ can replace albumin as a fat-soluble compound carrier in serum-free cell cultures.

IT 10016-20-3, α -Cyclodextrin

RL: BIOL (Biological study)

(as carrier, for fat-soluble compds. in astrocyte cell cultures)

RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 60-33-3, Linoleic acid, biological studies

RL: BIOL (Biological study)

(cyclodextrin as carrier for, in astrocyte cultures)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$_{\text{HO}_2\text{C}}$$
 (CH₂) 7 $_{\text{Z}}$ $_{\text{Me}}$

L25 ANSWER 28 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1992:590442 HCAPLUS

DOCUMENT NUMBER:

117:190442

TITLE:

Retarded oxidation of liquid lipids entrapped in

matrixes of saccharides or proteins

AUTHOR(S):

Imagi, Jun; Muraya, Koji; Yamashita, Daisuke; Adachi,

Shuji; Matsuno, Ryuichi

CORPORATE SOURCE:

SOURCE:

Fac. Agric., Kyoto Univ., Kyoto, 606-01, Japan Bioscience, Biotechnology, and Biochemistry (

1992), 56(8), 1236-40

CODEN: BBBIEJ; ISSN: 0916-8451

DOCUMENT TYPE:

Journal

English LANGUAGE: AB

Me linoleate (ML), linoleic acid (LA), and Et eicosapentaenoate (EE) were entrapped in saccharide and protein matrixes, and then stored at 37° in a desiccator controlled at 75% relative humidity. ML entrapped with α -cyclodextrin, maltodextrin, and pullulan was extremely resistant to autoxidn., but LA entrapped with maltodextrin and pullulan rapidly oxidized. LA entrapped with α -cyclodextrin was the most stable against oxidation ML entrapped with gelatin or gum arabic was less resistant to autoxidn. than that entrapped with pullulan; there was little difference in the susceptibility to oxidation between ML and LA entrapped with gelatin or gum arabic. Egg albumin protected ML more effectively against oxidation than LA, while sodium caseinate protected LA more than ML. EE entrapped with pullulan was highly resistant to oxidation, 90% of the total lipid remaining after 35 days. The effect on the oxidation of diffusion of oxygen through the matrix was estimated Retardation of oxidation of the entrapped lipid can not be explained only by the effect of diffusion.

60-33-3, Linoleic acid, biological studies IT


RL: RCT (Reactant); RACT (Reactant or reagent)

(autoxidn. of, entrapment in polysaccharides and proteins retardation of)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME) CN

Double bond geometry as shown.



10016-20-3, α -Cyclodextrin IT

RL: BIOL (Biological study)

(liquid lipids entrapment in, autoxidn. retardation by)

10016-20-3 HCAPLUS RN

 α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

L25 ANSWER 29 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:654556 HCAPLUS

DOCUMENT NUMBER: 115:254556

TITLE: Powderization of liquid-state lipids

AUTHOR(S): Matsuno, Ryoichi; Imagi, Jun

CORPORATE SOURCE: Agric. Coll., Kyoto Univ., Kyoto, Japan SOURCE: New Food Industry (1991), 33(5), 57-64

CODEN: NYFIAM; ISSN: 0547-0277

DOCUMENT TYPE: Journal LANGUAGE: Japanese

Liquid-state lipids (linoleic acid, Me linoleate, or Me oleate) were powderized by adsorption on gum arabic, starch, maltodextrin, α -cyclodextrin, maltose, glucose, or CM-cellulose. Lipids adsorbed on α -cyclodextrin, gum arabic, or CM-cellulose had high stability. The emulsifying activity of the lipid-adsorbent complex is described.

IT 10016-20-3, α-Cyclodextrin
RL: BIOL (Biological study)

(fatty acids and fatty acid Me esters adsorption on, for food application)

RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

60-33-3, Linoleic acid, biological studies IT

RL: BIOL (Biological study)

(powder, emulsifying activity of)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) CN (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

L25 HCAPLUS

ACCESSION NUMBER: 1991:404000 HCAPLUS

DOCUMENT NUMBER: 115:4000

Soybean lipoxygenase catalyzed oxygenation of TITLE:

unsaturated fatty acid encapsulated in cyclodextrin

Jyothirmayi, Nimmagadda; Ramadoss, Candadai S. AUTHOR (S):

Food Chem. Dep., Cent. Food Technol. Res. Inst., CORPORATE SOURCE:

Mysore, India

Biochimica et Biophysica Acta, Lipids and Lipid SOURCE:

Metabolism (1991), 1083(2), 193-200

CODEN: BBLLA6; ISSN: 0005-2760

Journal DOCUMENT TYPE: English LANGUAGE:

Linolic acid or arachidonic acid entrapped in cyclodextrin (α , AB β or γ) serves as an excellent substrate for soybean lipoxygenase-1 catalysis. At pH 9.0 the Km values for the β-cyclodextrin-encapsulated arachidonic acid, referred herein as encapsulated substrate, and the Tween-20-dispersed substrate were 7.7 and 7.5 μ M, resp. However, the Vmax values for α - and β-cyclodextrin-solubilized substrates were lower in comparison with the Tween-20-dispersed substrate. Interestingly, the pH-activity profile for the enzyme toward cyclodextrin-encapsulated arachidonic acid showed an optimum of .apprx.7.5, whereas that toward the Tween-20 dispersion showed the expected broad optimum in the alkaline range (8.5-10.0). The activity with encapsulated substrate at pH 7.5 was ≥5-fold higher than that obtained with Tween-20-dispersed substrate at the corresponding pH.

Similar results were obtained using linolic acid. The 2nd-order rate constant, kcat/Km, for the encapsulated substrate was an order of magnitude higher when compared to the Tween-20-dispersed substrate. The plot of velocity obtained at pH 9.0, against substrate concentration gave hyperbolic curves for both the encapsulated as well as the Tween-20-dispersed substrates, whereas at pH 7.5, the curve for cyclodextrin-encapsulated arachidonic acid appeared initially concave and then at higher concns. of the substrate, sigmoidal. The positional specificity of soybean lopoxygenase remained unaltered, however.

IT 7585-39-9, β -Cyclodextrin

RL: BIOL (Biological study)

(arachidonic acid encapsulated in, hydrolysis of, by lipoxygenase of soybean, kinetics of)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

OH OH H OH HO R R S R H OH HO H OH OH R H HO OH. HO----- R H OH OH HO R OH HO OH R OH HO H

PAGE 2-A

PAGE 1-A

Н

IT 60-33-3, Linoleic acid, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(cyclodextrin-encapsulated, hydrolysis of, by lipoxygenase of soybean)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Roy P. Issac

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

L25 ANSWER 31 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1989:453519 HCAPLUS

DOCUMENT NUMBER:

111:53519

TITLE:

Specific adsorbents in isolation and purification of

cyclodextrins

AUTHOR(S):

Makela, Mauri; Mattsson, Pekka; Korpela, Timo

CORPORATE SOURCE:

Dep. Biochem., Univ. Turku, Turku, SF-20500, Finland

SOURCE:

Biotechnology and Applied Biochemistry (1989

), 11(2), 193-200

CODEN: BABIEC; ISSN: 0885-4513

DOCUMENT TYPE: LANGUAGE: Journal English

AB A number of synthesized affinity sorbents were tested to find methods for the separation of α -, β -, and γ -cyclodextrins (CDs) from one another and from acyclic dextrins. None of the gels retarded acyclic

dextrins, whereas α -CD was specifically adsorbed onto supports derivatized with alkyl functions, β -CD was specifically adsorbed onto supports derivatized with phenyl or substituted Ph, and γ -CD was specifically adsorbed onto a gel derivatized with a naphthyl compound It was evident that for achievement of binding capacities high enough for

practical preparation of the CDs, various parameters such as the support material, its porosity, ligand, ligand concentration, temperature, and the composition of the mobile phase must be optimized.

IT 60-33-3D, 9,12-Octadecadienoic acid (Z,Z)-, derivs.

RL: ANST (Analytical study)

(for cyclodextrins isolation and purification by affinity liquid chromatog.)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

 HO_2C (CH₂) 7 Z Z (CH₂) 4 Me

IT 7585-39-9P, β-Cyclodextrin 10016-20-3P,

 α -Cyclodextrin 17465-86-0P, γ -Cyclodextrin


RL: PREP (Preparation)

(isolation and purification of, by affinity liquid chromatog., adsorbents in)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 2-A



RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

Roy P. Issac

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

L25 ANSWER 32 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1988:443459 HCAPLUS

DOCUMENT NUMBER:

109:43459

TITLE:

Pharmaceuticals containing unsaturated fatty acids and stimulators for synthesis of prostaglandin and hydroxy

fatty acids

INVENTOR(S):

Weithmann, Klaus Ulrich

PATENT ASSIGNEE(S):

Hoechst A.-G., Fed. Rep. Ger. Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 244832 EP 244832	A2 A3	19871111 19891129	EP 1987-106520	19870506 <
EP 244832	B1	19920624		
	DE, ES	, FR, GB, C	GR, IT, LI, LU, NL, SE	
DE 3615710	A1	19871126	DE 1986-3615710	19860509 <
AT 77549	${f T}$	19920715	AT 1987-106520	19870506 <
ES 2051705	T 3	19940701	ES 1987-106520	19870506 <
DK 8702356	\mathbf{A} .	19871110	DK 1987-2356	19870508 <
DK 167518	B1	19931115		
AU 8772641	A	19871112	AU 1987-72641	19870508 <
AU 603574	B2	19901122		
JP 62267222	A	19871119	JP 1987-110953	19870508 <
ZA 8703299	A	19871230	ZA 1987-3299	19870508 <
HU 44433	A2	19880328	HU 1987-2088	19870508 <
HU 201671	В	19901228		
CA 1302266	C	19920602	CA 1987-536688	19870508 <
IL 82459	A	19940731	IL 1987-82459	19870508 <

US 5043328 19910827 US 1989-304717 19890201 <--A DE 1986-3615710 A 19860509 PRIORITY APPLN. INFO.: EP 1987-106520 A 19870506 US 1987-46650 B3 19870507

OTHER SOURCE(S): MARPAT 109:43459 GI

$$R^{1}$$
 R^{2}
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{3}

The title composition contains ≥1 unsat. C18-22 fatty acid derivs. AB containing 3-5 isolated double bonds and which may be Me or Et substituted at the 2, 3, 16-20 position, selected from the free terminal carboxylic acids, amides, or CO2X derivs. (X = protecting group removable under acidic conditions, 1- or 2-lysophospholipid, metal cation, amine cation, cationic ion-exchanger). It also contains a stimulator with simultaneously stabilizing properties selected from ≥1 phenols I (R1 = OH, CO2H, CH2CO2H, CH:CHCO2H, CH2CHR4R5, CH(OH)CH2NHR6; R2, R3 = H,OH; R4 = H, CO2H; R5 = H, NH2; R6 = H, Me, Et]; indoles II (R7 = H, <math>CO2H; R8 = H, NH2; R9 = H, OH); cysteine, homocysteine, or liponic acid wherein the alicyclic alkyl residue may be shortened by <4 CH2-groups; a peptide containing ≤10 amino acids and in which ≥1 may be replaced by any of the above compds.; one of the above amino compds. substituted by C1-4 alkyl; a flavonoid substituted by ≥1 OH linked to a sugar residue; a salt of the above named compds.; as ester containing an alkoxy-containing residue, or its amide, mono- or dialkylamide. Addnl., it contains stabilizers selected from DMSO, EtOH, polyols, polyol esters, phospholipids, sugar lipids, cyclodextrins, proteins, cytochrome c derivs., or E-vitamins in solid or liquid form. A mixture containing 0.3 mL 0.03M K phosphate buffer, 0.5 mg enzyme (from sheep sperm vesicles or homogenate of kidney medulla), 2.75 μ g 14C-arachidonic acid, and 0.5 mg I [R1 = CH2CH(NH2)CO2H, R2 = R3 = H] (stimulator) was incubated for 10 min at 37° and quenched with citric acid. The formation of total prostaglandin increased 5.5-fold over the amount formed in the absence of a stimulator; the relative amts. of PGE2, PGF2 α , and PGD2 with stimulator were 81, 2, and 17%, resp., and 83, 2, and 15%, resp., in the absence of a stimulator.

60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies IT RL: BIOL (Biological study)

(pharmaceutical containing prostaglandin synthesis stimulator and)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME) CN


Double bond geometry as shown.

$$_{\text{HO}_2\text{C}}$$
 (CH₂) 7 $_{\text{Z}}$ $_{\text{Z}}$ (CH₂) 4 $_{\text{Me}}$


7585-39-9, β-Cyclodextrin 10016-20-3, IT α -Dextrin 17465-86-0, γ -Dextrin RL: BIOL (Biological study) (pharmaceutical containing unsatd. fatty acids and, as prostaglandin synthesis stimulator) RN 7585-39-9 HCAPLUS CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

L25 ANSWER 33 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1986:477674 HCAPLUS

DOCUMENT NUMBER:

105:77674

TITLE:

Stabilization of lipids by molecular inclusion:

cyclodextrins and casein as antioxidants

AUTHOR (S):

Laakso, Simo

CORPORATE SOURCE:

Dep. Biochem., Univ. Turku, Turku, 20500, Finland Lipid Oxid.: Biol. Food Chem. Aspects, Contrib.

SOURCE:

LIPIDFORUM/SIK Symp. (1986), Meeting Date

1985, 165-70. Editor(s): Marcuse, Reinhard. Scand.

Forum Lipid Res. Technol.: Goeteborg, Swed.

Roy P. Issac

Page 84

CODEN: 55ATAL

DOCUMENT TYPE:

Conference

LANGUAGE:

English

The effects of cyclodextrin and casein inclusion on the kinetics of linoleic acid [60-33-3] and arachidonic acid [506-32-1] oxidation in dispersions containing lipoxygenase or Na bisulfite were evaluated by monitoring free radical side reactions and O consumption. The fatty acid peroxidn. inhibition by casein was primarily by reversible inclusion of the free polyunsatd. fatty acid. Cyclodextrins and casein inhibited both enzymic and nonenzymic peroxidn. Inhibitor consts. were relatively high unless the concentration of fatty acids was limiting.

IT 7585-39-9 10016-20-3 17465-86-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(antioxidant activity of, polyunsatd. fatty acids inclusion in relation to)

RN 7585-39-9 HCAPLUS


CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

IT 60-33-3, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)
(peroxidn. of, casein and cyclodextrins inhibition of)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$(CH_2)$$
 7 Z (CH_2) 4 Me

Page 86

L25 ANSWER 34 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:164689 HCAPLUS

DOCUMENT NUMBER: 104:164689

TITLE: Growth of an established line of mouse mammary tumor

cells under serum-free conditions

AUTHOR(S): Kawamura, Kazuo; Enami, Jumpei; Kohmoto, Kaoru; Koga,

Mutuyosi

CORPORATE SOURCE: Sch. Med., Dokkyo Univ., Mibu, 321-02, Japan SOURCE: Dokkyo Journal of Medical Sciences (1985),

12/2) 167 00

12(2), 167-80

CODEN: DJMSDB; ISSN: 0385-5023

DOCUMENT TYPE: Journal LANGUAGE: English

An established line of mouse mammary tumor cells (MTD cells) were cultured AB in a serum-free medium consisting of a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium supplemented with bovine serum albumin (BSA), insulin, and transferrin. To promote cell attachment and spreading, culture dishes were precoated with plasma fibronectin isolated from fibrinogen. Under these serum-free conditions, MTD cells grew at a rate close to that attained by the serum-supplemented medium. Among the additives in the serum-free medium, BSA was replaced with oleic acid or a complex of oleic acid and α -cyclodextrin. Transferrin was replaced with Fe2+ or Fe3+. Addition of polyvinylpyrrolidone further improved the growth. Thus, MTD cells can be grown on a fibronectin-coated surface in a chemical defined medium with insulin as the only protein supplement. MTD cells grown under the serum-free conditions still retained the differentiated properties of the original MTD cells; i.e., the production of mouse mammary tumor virus in response to dexamethasone.

IT 60-33-3, biological studies 10016-20-3


RL: BIOL (Biological study)

(mouse mammary tumor cells in culture response to)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 10016-20-3 HCAPLUS

CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

L25 ANSWER 35 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1984:81327 HCAPLUS

DOCUMENT NUMBER: 100:81327

TITLE: Inhibition of lipid peroxidation by casein. Evidence

of molecular encapsulation of 1,4-pentadiene fatty

acids

AUTHOR(S): Laakso, Simo

CORPORATE SOURCE: Dep. Biochem., Univ. Turku, Turku, SF-20500/50,

Finland

SOURCE: Biochimica et Biophysica Acta, Lipids and Lipid

Metabolism (1984), 792(1), 11-15 CODEN: BBLLA6; ISSN: 0005-2760

DOCUMENT TYPE: Journal LANGUAGE: English

The capability of cyclodextrins to form mol. inclusion complexes with AB linoleate resulted in inhibition of oxygenation in a lipoxygenaselinoleate model reaction. The inhibited rates were established instantaneously upon addition of the complexant and were maintained until linoleate was exhausted. Total cessation of the reaction was not obtained with cyclodextrins. Casein-inhibited reaction mixts. also exhibited these characteristics. Both casein and cyclodextrins protected linoleate against autoxidn., although they did not change free radical generation by xanthine oxidase or Fe2+ reactions. Since neither of the inhibitors affected the enzyme directly, casein may act, in analogy with cyclodextrins, by forming linoleate complexes which reduce the oxidizable monomer fatty acids via a standing equilibrium and thus result in substrate limitation of reaction rates. Comparisons of lipid peroxidn. at acidic and alkaline pH, in the presence of increasing amts. of the complexants, detergent, and hydroperoxides, supported this view.

IT 7585-39-9 10016-20-3 17465-86-0

RL: BIOL (Biological study)

(linoleate peroxidn. inhibition by, mechanism of, casein in relation to)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

HO-CH2

IT 60-33-3, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)
 (peroxidn. of, enzymic and spontaneous, casein and cyclodextrins
 inhibition of, mechanism of)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

L25 ANSWER 36 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:124329 HCAPLUS

DOCUMENT NUMBER: 98:124329

TITLE: Oxidative degradation of β-cyclodextrin induced

by lipid peroxidation

AUTHOR(S): Kawakishi, S.; Satake, A.; Komiya, T.; Namiki, M.

CORPORATE SOURCE: Mie Univ., Nagoya, 514, Japan

SOURCE: Starch/Staerke (1983), 35(2), 54-7

CODEN: STARDD; ISSN: 0038-9056

DOCUMENT TYPE: Journal LANGUAGE: English

The oxidative degradation of β -cyclodextrin (β -CD) [7585-39-9] induced by autoxidn. of linoleate [60-33-3] was investigated in th solid system composed of β -CD and linoleate. β -CD was oxidized with a propagative oxidation of linoleate to induce the cleavage of its glucosidic linkage and this degradation proceeded proportionally with the moisture content in the solid system. The oxidative cleavage of β -CD gave several kinds of oligosaccharides which were composed of D-erythrose, D-arabinose, D-erythropentosulose, D-xylopentdialdose, D-glucose and deoxyunsatd. hexose as their reducing

terminals. These degradation of $\beta\text{-CD}$ seemed to be initiated by certain radical species formed from the peroxidn. of linoleate.

IT 7585-39-9

RL: PRP (Properties)


(degradation of, by linoleic acid peroxidn., products from)

RN 7585-39-9 HCAPLUS


CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 60-33-3, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(peroxidn. of, cyclodextrin degradation by, products from)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$(CH_2)_7$$
 Z $(CH_2)_4$ Me

L25 ANSWER 37 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1982:612006 HCAPLUS

97:212006 DOCUMENT NUMBER:

 α -Cyclodextrin: a partial substitute for bovine TITLE:

serum albumin in serum-free culture of mammalian cells

Yamane, Isao; Kan, M.; Minamoto, Y.; Amatsuji, Y. AUTHOR(S):

Inst. Tuberculosis Cancer, Tohoku Univ., Sendai, 980, CORPORATE SOURCE:

Japan

Cold Spring Harbor Conferences on Cell Proliferation (SOURCE:

1982), 9(Growth Cells Horm. Defined Media,

Book A), 87-92

CODEN: CSHCAL; ISSN: 0097-5230

Journal DOCUMENT TYPE: English LANGUAGE:

The use was investigated of oleic acid- or linoleic acid- α -AB cyclodextrin inclusion complexes as albumin substitutes for mammalian cells. α-Cyclodextrin did not show any cytotoxic effects at 2g/L

medium. Growth curves are shown for 2 types of cells. UMCL cells grew

well enough in the cyclodextrin-complex-containing, serum-free medium, whereas HEL cells required a small amount of albumin in addition to cyclodextrin for

abundant growth.

60-33-3D, α -cyclodextrin inclusion complexes IT

10016-20-3 10016-20-3D, fatty acid inclusion complexes

RL: ANST (Analytical study)

(as albumin substitute, in serum-free cultures of mammalian cells)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME) CN

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

10016-20-3 HCAPLUS RN

 α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

10016-20-3 **HCAPLUS** RN

 α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

L25 ANSWER 38 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1982:100488 HCAPLUS

DOCUMENT NUMBER: 96:100488

TITLE: α -Cyclodextrin, a novel substitute for bovine

albumin in serum-free culture of mammalian cells

AUTHOR(S): Yamane, Isao; Kan, Mikio; Minamoto, Yoshiki; Amatsuji,

Yasuo

CORPORATE SOURCE: Res. Inst. Tuberc. Cancer, Tohoku Univ., Sendai, 980,

Japan

SOURCE: Proceedings of the Japan Academy, Series B: Physical

and Biological Sciences (1981), 57(10),

385-9

CODEN: PJABDW; ISSN: 0386-2208

DOCUMENT TYPE: Journal LANGUAGE: English

AB The use of α -, β -, and γ -cyclodextrin (CD) in combination with unsatd. fatty acids as a serum substitute in mammalian cell cultures was examined by using a human lymphoblast cell line (UMCL) grown in RITC 56-1 medium supplemented with synthetic lecithin, cholesterol, galactose, and mannose and by using human diploid fibroblasts (HEL) grown in RITC 80-7 medium. On the basis of cytotoxic and cost considerations, α -CD was used for the expts. Both α -CD-oleic acid and α -CD-linoleic acid had growth-enhancing effects on UMCL cells up to 100 mg/L medium but exhibited toxic effects at higher concns. However, when 100 mg α -CD included with both fatty acids and 1000 mg free α -CD were added to 1 L of medium, stable and reproducible growth-promoting effects were observed. With HEL cells, growth similar to that in bovine serum albumin-supplemented medium was observed by addition of a concentrated α -CD complex to a final concentration of 10-20 mg/L.

IT 7585-39-9


RL: ANST (Analytical study)

(mammalian cell culture containing, cytotoxic effect of)


RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 17465-86-0

RL: ANST (Analytical study)

(mammalian cell culture containing, growth enhancing effect of)

RN 17465-86-0 HCAPLUS

CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

10016-20-3 IT

RL: ANST (Analytical study)

(mammalian cell culture containing, growth-enhancing effect of)

10016-20-3 HCAPLUS RN

 α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

60-33-3, biological studies IT

RL: BIOL (Biological study)

(mammalian cell culture containing, in cyclodextrin presence,

growth-enhancing effect of)

60-33-3 HCAPLUS RN

9,12-Octadecadienoic acid (9Z,12Z).- (9CI) (CA INDEX NAME) CN

Double bond geometry as shown.

$$_{\text{HO}_2\text{C}}$$
 (CH₂) 7 $_{\text{Z}}$ $_{\text{Me}}$

L25 ANSWER 39 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1980:22061 HCAPLUS

DOCUMENT NUMBER: 92:22061

TITLE: Enrichment of the unsaturated fatty acid content in

fatty acid mixtures by formation of inclusion

complexes with cyclodextrin

INVENTOR(S): Szejtli, Jozsef; Banky, Mrs. Tamas; Stadler, Mrs.

Istvan; Tetenyi, Peter; Hethelyi, Mrs. Ivan; Kernoczi,

Mrs. Lajos

PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt.,

Hung.

SOURCE: Hung. Teljes, 18 pp.

CODEN: HUXXBU

DOCUMENT TYPE: Patent Hungarian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 16602	A2	19790328	HU 1977-CI1730	19770420 <
нт 174279	В	19791228		

PRIORITY APPLN. INFO.: HU 1977-CI1730 A 19770420

The stability of complexes of fatty acids and lower esters with cyclodextrin increases with the number of C:C double bonds present in the mol. This was used to enrich the unsatd. content of fatty acid mixts. by 5-50%. Thus, an oil extracted from seeds of Oenothera biennis was esterified with EtOH and a solution of 1 g ester in 5 mL Et2O was added in 10 min to a solution of 5 g anhydrous β-cyclodextrin in 50 mL H2O at 60° under N. After evaporation of Et2O the aqueous mixture was cooled to 20° in 4 h and kept overnight in the refrigerator to deposit 82% complex containing 10.1% fatty acid. It was washed with Et2O, dissolved in warm H2O, the solution was extracted with 1:1 Et2O-petroleum ether, saturated with NaCl, and extracted again. The proportion of linoleic acid/oleic acid increased from 5.14 to 13.7 by this procedure.

IT 7585-39-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(enrichment of unsatd. fatty acid content in fatty acid mixts. by
inclusion complexation with)

RN 7585-39-9 HCAPLUS

CN β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A



Н

PAGE 2-A

IT 60-33-3P, preparation RL: PREP (Preparation)

(enrichment of, in fatty acids of Oenothera biennis)

RN 60-33-3 HCAPLUS

CN 9,12-Octadecadienoic acid (9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$HO_2C$$
 (CH₂) 7 Z Z (CH₂) 4 Me

L25 ANSWER 40 OF 40 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1956:23995 HCAPLUS

DOCUMENT NUMBER: 50:23995

ORIGINAL REFERENCE NO.: 50:4858g-i,4859a-e

TITLE: Stabilization of autoxidizable materials by means of

inclusion

AUTHOR(S): Schlenk, Hermann; Sand, Donald M.; Tillotson, Jerry

Ann

CORPORATE SOURCE: Univ. of Minnesota, Austin

SOURCE: Journal of the American Chemical Society (1955)

), 77, 3587-90

CODEN: JACSAT; ISSN: 0002-7863

Journal DOCUMENT TYPE: Unavailable LANGUAGE:

Adducts of α -dextrin (cyclohexaamylose) (I), β -dextrin AB (cycloheptaamylose) (II) and deoxycholic acid (III) were prepared with linoleic acid (IV), linolenic acid (V), Me linolenate (VI), PhCH:CHCHO (VII), and vitamin A palmitate (VIII). They were found to be very resistant to autoxidation. The conventional procedure of preparing choleic acids yielded stable products with V and VIII. The products obtained from dextrins with IV, V, and VII needed purification. A heat treatment under high vacuum was found to be reliable for obtaining stable adducts free of oxidizable contamination. The principle of inclusion stabilization appears to be established by these examples and by the previous work on fatty acid stabilization by means of urea (C.A. 44, 11123f). II (8 g.) in 100 cc. O-free 50% aqueous EtOH treated at about 70° with 1.3 g. IV, the mixture stirred 4 hrs. at room temperature and centrifuged, and the solid dried over P205 at 0.5 mm. gave 7.7 g. II-IV adduct containing 7.28 g. IV (titrated in hot 50% aqueous EtOH with 0.05N KOH and phenolphthalein. II-IV adduct sublimed after rinsing with N under a high vacuum 9 hrs. at 120-5° gave 6.9% IV. Purified II-IV adduct (1.63 g.) in 100 cc. hot 50% aqueous EtOH extracted twice with 50-cc. portions trimethylpentane, the extract dried and evaporated, the residual oil brominated in Skellysolve F, and the resulting white crystals (75 mg.) repptd. from warm Et20 with Skellysolve F yielded 47 g. tetrabromostearic acid, m. 115-16.5°. II (1.6 g.) and 0.32 g. V treated in the usual manner in 20 cc. aqueous EtOH, the solids isolated and heated 17 hrs. at 122° and 0.5 mm. pressure, two 0.7-g. portions of the residue (each containing 67 mg. V) exposed to pure O in a Warburg apparatus (the manometers being filled with silicone fluid) at $37 \pm 0.2^{\circ}$ (one in a dry and one in a humid atmospheric) and the charge brominated in the usual manner gave eventually hexabromostearic acid. The II-VI adduct containing 10.8% VI was obtained in the same manner. II (5.0 g.) in 100 cc. H2O and 0.9 g. VII shaken 16 hrs. at room temperature, the solids isolated in the usual manner and heated 3 hrs. at 100-40° and 0.5 mm. gave an adduct containing 10.5% (9.6%) VII (determined as the 2,4-dinitrophenylhydrazone, m. 258-9°) and 0.3% (1.3%) PhCH:CHCO2H. I (2.0 g.) in 15 cc. O-free H2O warmed to 70° with IV in 15 cc. EtOH, the mixture kept 4 hrs. at room temperature, the crystals isolated by centrifugation and dried, and a part heated to 130-60° during 16 hrs. at 0.5 mm. gave I-IV adduct (115 μ l. O uptake during 40 hrs. under standard conditions); another part of the crude product digested with 10 cc. EtOH gave I-IV adduct (760 µl. O-uptake). III (6.0 g.) in 20 cc. absolute EtOH and 0.55 g. V in 5 cc. EtOH kept 16 hrs. at -5 to -10° gave III-V adduct containing 8.3% V. The adduct was refluxed 1 hr. with 8 times its weight of xylene, the III-xylene adduct filtered and washed with C6H6, the combined xylene and C6H6 solution evaporated, the oily residue extracted with Skellysolve C, the extract evaporated, and the residue titrated with alkali to determine the acid content. III (1.0 q.) and 0.1 g. VIII in 4 cc. hot EtOH cooled to room temperature, held 12 hrs. at -3°, and the light yellow crystals filtered and dried in a high vacuum gave the III-VIII adduct containing 10.8% VIII. 7585-39-9, Cycloheptaamylose 10016-20-3, Cyclohexaamylose

IT

(inclusion compds. with autoxidizable materials)

7585-39-9 HCAPLUS RN

β-Cyclodextrin (8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

Roy P. Issac Page 98

PAGE 1-A

PAGE 2-A


RN 10016-20-3 HCAPLUS CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

10/712,703>07/02/2007

IT 60-33-3, Linoleic acid (oxidation of, prevention of aut-, by inclusion compound formation)

RN 60-33-3 HCAPLUS CN 9,12-Octadecadienoic acid (9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



Roy P. Issac